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Abstract
Mapping clinical outcomes to generic preference-based
outcome measures: development and comparison of methods
Mónica Hernández Alava ,1* Allan Wailoo ,1 Stephen Pudney ,1
Laura Gray 1 and Andrea Manca 2
1School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
2Centre for Health Economics, University of York, York, UK
*Corresponding author monica.hernandez@sheffield.ac.uk
Background: Cost-effectiveness analysis using quality-adjusted life-years as the measure of health
benefit is commonly used to aid decision-makers. Clinical studies often do not include preference-
based measures that allow the calculation of quality-adjusted life-years, or the data are insufficient.
‘Mapping’ can bridge this evidence gap; it entails estimating the relationship between outcomes
measured in clinical studies and the required preference-based measures using a different data set.
However, many methods for mapping yield biased results, distorting cost-effectiveness estimates.
Objectives: Develop existing and new methods for mapping; test their performance in case studies
spanning different preference-based measures; and develop methods for mapping between preference-
based measures.
Data sources: Fifteen data sets for mapping from non-preference-based measures to preference-based
measures for patients with head injury, breast cancer, asthma, heart disease, knee surgery and varicose
veins were used. Four preference-based measures were covered: the EuroQoL-5 Dimensions, three-
level version (n = 11), EuroQoL-5 Dimensions, five-level version (n = 2), Short Form questionnaire-6
Dimensions (n = 1) and Health Utility Index Mark 3 (n = 1). Sample sizes ranged from 852 to 136,327.
For mapping between generic preference-based measures, data from FORWARD, the National
Databank for Rheumatic Diseases (which includes the EuroQoL-5 Dimensions, three-level version,
and EuroQoL-5 Dimensions, five-level version, in its 2011 wave), were used.
Main methods developed: Mixture-model-based approaches for direct mapping, in which the
dependent variable is the health utility value, including adaptations of methods developed to model
the EuroQoL-5 Dimensions, three-level version, and beta regression mixtures, were developed,
as were indirect methods, in which responses to the descriptive systems are modelled, for consistent
multidirectional mapping between preference-based measures. A highly flexible approach was
designed, using copulas to specify the bivariate distribution of each pair of EuroQoL-5 Dimensions,
three-level version, and EuroQoL-5 Dimensions, five-level version, responses.
Results: A range of criteria for assessing model performance is proposed. Theoretically, linear
regression is inappropriate for mapping. Case studies confirm this. Flexible, direct mapping methods,
based on different variants of mixture models with appropriate underlying distributions, perform
very well for all preference-based measures. The precise form is important. Case studies show that a
minimum of three components are required. Covariates representing disease severity are required as
predictors of component membership. Beta-based mixtures perform similarly to the bespoke mixture
approaches but necessitate detailed consideration of the number and location of probability masses.
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The flexible, bi-directional indirect approach performs well for testing differences between preference-
based measures.
Limitations: Case studies drew heavily on EuroQoL-5 Dimensions. Indirect methods could not be
undertaken for several case studies because of a lack of coverage. These methods will often be
unfeasible for preference-based measures with complex descriptive systems.
Conclusions: Mapping requires appropriate methods to yield reliable results. Evidence shows that
widely used methods such as linear regression are inappropriate. More flexible methods developed
specifically for mapping show that close-fitting results can be achieved. Approaches based on mixture
models are appropriate for all preference-based measures. Some features are universally required
(such as the minimum number of components) but others must be assessed on a case-by-case basis
(such as the location and number of probability mass points).
Future research priorities: Further research is recommended on (1) the use of the monotonicity
concept, (2) the mismatch of trial and mapping distributions and measurement error and (3) the
development of indirect methods drawing on methods developed for mapping between preference-
based measures.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 24, No. 34. See the NIHR Journals Library website for further project information. This project
was also funded by a Medical Research Council grant (MR/L022575/1).
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Plain English summary
Coherent decisions about which health services and treatments to provide rely on economicanalysis to weigh potential health benefits against costs. For decisions to be consistent across the
whole health service, benefits need to be counted in the same way for patients with different health
problems. This is accomplished by using a unit of measurement for treatment outcomes called the
quality-adjusted life-year. The best way to calculate quality-adjusted life-years is to ask patients taking
part in clinical studies to fill in specially designed questionnaires to describe their health in a simple,
standardised way. However, clinical trials often record patient outcomes in different ways, leaving
economic analysts without the necessary information to calculate quality-adjusted life-years. A way to
overcome this problem (known as ‘statistical mapping’) is to use the available clinical data to predict
the responses that would have been made by trial participants to the standard questionnaire. This
requires analysis of data from an additional study in which patients have provided both types of
outcome data to construct a statistical ‘mapping model’.
Mapping is widely used in practice, but it is often based on simple mapping models that in some
circumstances systematically mispredict and may consequently give a false picture of the real health
benefits of treatments. This is important because it influences decisions about which treatments are
available in the NHS; it has real effects on patients, clinicians, industry and the general public.
Our objectives are to develop promising new statistical mapping models specifically designed for
different clinical contexts and to compare them using patient data in different disease areas. We have
also developed an approach for judging the outcome of a mapping study. We find that the new
methods work better than existing methods in terms of their ability to fit the data and avoid
systematic bias.
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Scientific summary
Background
Cost-effectiveness analysis using quality-adjusted life-years as the measure of health benefit is commonly
used to aid decision-makers in health systems the world over. However, to calculate the quality-adjusted
life-year benefits of different health technologies, policies or other types of interventions, it is necessary
for clinical studies to include the correct types of outcome measures. Specifically, there are a range of
preference-based measures that can be used. These preference-based measures comprise a survey
instrument that is used to describe the health of an individual and a set of values for the health states
that can be described. These values are typically derived from a sample of the general population using
valuation methods that have some basis in economic theory. However, frequently, preference-based
measures are entirely absent from clinical studies, or preference-based measures inappropriate for
the setting are used, or the preference-based measure data from the studies are insufficient for the
calculation of cost-effectiveness. In such circumstances, ‘mapping’ can bridge the evidence gap. Mapping
entails estimating a statistical relationship, usually between clinical or other non-preference-based
measures that have been used in clinical studies and the required preference-based measure for the
economic analysis. To accomplish this, a different data set needs to be found in which both the required
preference-based measure absent from the clinical study and the clinical or other non-preference-based
measures used in the clinical study are present. Mapping is a widely employed method. However,
mapping studies have often used methods that perform poorly, yield biased results and have a substantial
impact on estimates of cost-effectiveness.
Objectives
l Further develop existing methods for mapping and develop new methods appropriate to the
characteristics of health utility data.
l Develop methods for assessing mapping models for use in economic evaluation.
l Test the performance of mapping methods in data sets with differing characteristics, including a
range of target preference-based measures.
l Develop methods for mapping between different preference-based measures that are specifically
designed to allow the estimation of health benefits in one outcome measure or the other.
l Produce commands that allow other researchers to apply the statistical methods developed using
standard statistical software.
l Identify key areas for further research.
Methods
Methods development
Health utility data are characterised by complex distributions that pose challenges for conventional
statistical methods.
There are two approaches to mapping:
l direct mapping
¢ one-step process
¢ mapping specific to each country’s utility
¢ needs responses across the full range of disease severity.
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l indirect mapping
¢ two steps
¢ can use the same model for different countries
¢ needs enough responses at all levels in each dimension.
We developed and tested the performance of a series of mixture-model-based approaches for direct
mapping in which the dependent variable is the health utility value. The adjusted limited dependent
variable mixture model was originally developed in the context of the EuroQoL-5 Dimensions, three-
level version, for the UK. It is based on mixtures of bespoke distributions that reflect the limits to the
EuroQoL-5 Dimensions, three-level version, distribution at full health, at the worst health state and
the substantial gap between full health and the next feasible health state. Other preference-based
measures have less pronounced gaps than the EuroQoL-5 Dimensions, three-level version (using the
UK value set), but they are all limited at both the top and the bottom of the health distribution. At the
top, they are bounded by a common value, 1, representing full health. At the bottom, they are bounded
at values that differ according to the worst health state defined by each preference-based measure.
Whether or not there are large proportions of observations at any of these boundary points is also
dependent on the specific characteristics of the patients of interest and the preference-based measure
instrument. In this work, we further developed the adjusted limited dependent variable mixture model
to allow options that reflect these different characteristics across preference-based measures: different
boundaries at the bottom of the health utility distribution and the option to include/exclude the gap
between full health and the next value in the health utility distribution using the gap relevant to each
specific preference-based measure.
We developed beta-based mixture models that are a generalisation of the truncated inflated beta
regression. The beta distribution is defined in the zero–one domain and does not allow observations at
the boundaries. The general model developed here transforms the health utility data to the zero–one
range so that the beta distribution can be used. It also allows observations at the boundaries via a
choice of (1) adding a small amount of noise to the boundary observations if they are small in number
or (2) allowing the inclusion of probability masses at those boundaries. Inclusion of the gap between
full health and the next utility value, as well as a mass point at this value, are also options.
The developed direct approach models are also compared with standard indirect method approaches.
Indirect methods, also known as response mapping, use a two-stage approach. First, the responses to
the preference-based measure descriptive system are modelled. The expected utility value is calculated
as a second step. These methods were tested where available data sets allowed them to be estimated.
We also developed an indirect approach for the case of mapping between preference-based measures.
The mapping methods described above are designed to predict a preference-based measure from a set
of non-preference-based measures used as explanatory variables. There is no necessity to map in the
opposite direction. Therefore, mapping between preference-based measures requires further extension
of methods to allow mapping in either direction in a mutually consistent way. The model was developed
for mapping between the EuroQoL-5 Dimensions, three-level version, and EuroQoL-5 Dimensions,
five-level version, but the general model can be used for any preference-based measures. We designed
an approach that is as flexible as possible to avoid imposing unnecessary restrictions that could lead to
inconsistent estimates. The structural parts of the model are allowed to differ between the preference-
based measures, thus permitting post-estimation testing of hypotheses regarding the preference-based
measures. The bivariate distribution between each pair of responses is specified using copulas, which
allows the patterns of associations to differ across different dimensions of the preference-based
measures and the strength of the association to differ at different parts of the health distribution.
The model also relaxes the normality assumption underlying ordinal equations and incorporates a
random latent factor to reflect individual-specific effects affecting the individual’s responses across
all dimensions of both preference-based measures.
SCIENTIFIC SUMMARY
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There have been claims that mapping underestimates the degree of uncertainty for health state values.
We demonstrate the difference between uncertainty and variability in the context of mapping models.
We propose the use of graphical representations to compare like with like, that is, (1) the predictions
from the models with the conditional sample means and (2) the distribution implied by the estimated
model with the distribution of the sample data. We show how these can be used to judge model
performance and to assess uncertainty for use in cost-effectiveness analyses.
In addition to developing mapping models, we also considered other methodological issues around
mapping. First, we examined the extent of conflicts between the orderings of health states in a case
study of the EuroQoL-5 Dimensions, three-level version, and EuroQoL-5 Dimensions, five-level version.
Two instruments are monotonic if both order two health states unambiguously in the same way.
Substantial failures of monotonicity present problems for mapping. Second, we investigated the issue
of measurement error. There are many potential sources of measurement error in the health outcomes
used in mapping: some are present in the responses to the variables being modelled in the mapping
study, some are present when those same measures are used in clinical studies. Furthermore, we
investigated the consequences of distributional mismatch between the trial target population and the
population used for mapping as an additional source of bias.
Data
For mapping from non-preference-based measures to preference-based measures, seven case studies
provided 15 data sets for estimation of mapping models. These studies were from patients with head
injury, breast cancer (two case studies), asthma, heart disease, knee surgery and varicose veins. All four
of the most widely used preference-based measures were considered in these case studies (though
we concentrate on the two variants of the more commonly encountered EuroQoL-5 Dimensions):
EuroQoL-5 Dimensions, three-level version (n = 11), EuroQoL-5 Dimensions, five-level version (n = 2),
Short Form questionnaire-6 Dimensions (n = 1) and Health Utility Index Mark 3 (n = 1). Studies ranged
in terms of sample size from 852 to 136,327 and were collected from randomised clinical trials, disease
registries, bespoke patient survey studies and the UK NHS Patient Reported Outcome Measures
(PROMs) programme.
For mapping between generic preference-based measures we used data from FORWARD, the National
Databank for Rheumatic Diseases, which included both the EuroQoL-5 Dimensions, three-level version,
and the EuroQoL-5 Dimensions, five-level version, in its 2011 wave (n = 4856).
Results
Figure a summarises the methods and variants tested in the case studies.
Mapping methods Variants
Multidirectional
Unidirectional
Direct
Indirect
Linear regression
ALDVMM
Beta mixtures
Response mapping
Response mapping
Number of components
Gap at upper end or not
Number and location of probability mass points
Generalised ordered probits
Seemingly unrelated ordered probits
Systems of ordered regressions using different copulas
FIGURE a Summary of methods and variants tested. ALDVMM, adjusted limited dependent variable mixture model.
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We demonstrate that there are problems with commonly used standard models. Linear regression is
shown to be theoretically inappropriate for bounded data. Two-part models are designed to be applied
to data which have a large proportion of observations at full health, but the approach is not flexible
enough to deal with other challenges posed by health utility data. We show the importance of using
appropriate model selection criteria to expose poor performance. In the case studies that examine
methods for mapping from non-preference-based measures, we found that linear regression does not
perform well, as predicted theoretically.
Flexible, direct mapping methods based on different variants of mixture models, with appropriately
specified underlying distributions, perform very well for all preference-based measures, but the
precise form is important. The case studies show that a minimum of three components are required.
Covariates representing disease severity are required as predictors of component membership in all
cases. Beta-based mixture models show similar performance to the adjusted limited dependent variable
mixture model approaches but generally necessitate detailed consideration of the number and location
of probability masses owing to the inability of the beta distribution to accommodate observations at
the boundary values. Even for preference-based measures for which the gap between full health and
the next feasible health state is much less pronounced than for the EuroQoL-5 Dimensions, three-level
version (UK value set), explicitly allowing for this gap in the statistical model matters. Results were
more variable regarding the optimal number of components and whether or not more than four could
be estimated given the data, inclusion of probability masses at different points (upper and lower
boundaries of the preference-based measure as well as the truncation point if a gap is included),
covariates, their form and whether they appear within the components or in the component
probabilities. Good practice needs to be followed in estimation to ensure that the models have
genuinely converged.
Response mapping methods did not perform as well as direct mapping approaches in the three case
studies in which these were applied. In some cases, response mapping could not be estimated because
of lack of observations in each response category of the descriptive system of the preference-based
measure.
We used the data and estimated models from six case study examples to demonstrate that mapping,
from simple or complex direct methods or from indirect methods, does not underestimate uncertainty.
Econometric modelling based on a flexible mixture–copula specification response mapping model
revealed significant differences between patients’ responses to the three-level and five-level versions
of the EuroQoL-5 Dimensions descriptive system. These differences were particularly striking for the
mobility and pain domains, which are the most important dimensions of EuroQoL-5 Dimensions for
patients with rheumatoid disease, the disease area of the estimation study. With regard to the health
utility values, EuroQoL-5 Dimensions, five-level version, values had a tendency to be systematically
higher than those of the EuroQoL-5 Dimensions, three-level version. We showed in an economic
evaluation (of rheumatoid arthritis) case study that, as a direct consequence of these differences, the
magnitude of the incremental cost-effectiveness ratio increased by > 100% in some cases when using
the EuroQoL-5 Dimensions, five-level version, instead of the EuroQoL-5 Dimensions, three-level
version, as used in the original economic evaluation.
We produced code in Stata® versions 14 and 15 (StataCorp LP, College Station, TX, USA) that allows
the implementation of the methods developed as part of this project. Specifically, we wrote the
Stata commands aldvmm and betamix to allow analysts to estimate mixture models appropriate for
health utility data. We also wrote the Stata command bicop, which allows estimation of a simplified
version of the flexible mixture-copula specification response mapping model. The command eq5dmap
maps between the EuroQoL-5 Dimensions, three-level version, and EuroQoL-5 Dimensions, five-level
version, in both directions from either the five-item health descriptions or the (exact or approximate)
health utility score.
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Conclusions
Mapping requires appropriate methods to yield reliable results. The appropriate methods should be
judged by reference to (1) comparisons of the predictions with means of the data, grouped according
to at least one of the conditioning variables, and (2) comparisons of the distribution of the data with
the distribution of the data implied by the estimated model inter alia.
Widely used methods such as linear regression are not appropriate theoretically. Results from case
studies clearly align with this position.
More flexible methods developed specifically for the purpose of unidirectional mapping show that
close-fitting results can be achieved. The approaches based on mixture models that were developed
here, namely the adjusted limited dependent variable mixture model and the beta-based mixture, are
recommended for all preference-based measures. The precise form of these model types is important
and were developed specifically to reflect the idiosyncrasies of health utility data. Some features are
universally required but other features must be assessed on a case-by-case basis.
Case studies draw heavily on the EuroQoL-5 Dimensions because this is the most widely used
preference-based instrument in UK policy and there are far fewer suitable data sets that use the Short
Form questionnaire-6 Dimensions or Health Utility Index Mark 3.
Response mapping from non-preference-based measures to preference-based measures could not be
undertaken for several case studies because of the lack of coverage, though this itself is revealing in
relation to the feasibility of response mapping of preference-based measures with more complex
descriptive systems.
The response mapping model developed specifically for multidirectional mapping performed very well.
The two-step process of the response mapping approach was very useful in this case because it
separates the responses to the descriptive system from the utility values attached to health states
and, therefore, was able to uncover important differences between both versions of the EuroQoL-5
Dimensions.
We found that lack of monotonicity, distributional mismatch between the clinical study population
and the population of the mapping study, and measurement error are all potential sources of bias.
Illustrative case studies and calibration models showed that these biases might be substantial.
Recommendations for future research
Further research is needed to gain a better understanding of the problems posed by lack of monotonicity
and the extent to which it affects different preference-based measures and non-preference-based
measures. Furthermore, future research should examine the use of monotonicity measures for informing
mapping studies.
Additional research is needed to understand the likely size of the biases due to distributional mismatch
between the trial target population and the population used for mapping.
Given the different potential sources of measurement error in the outcomes used in mapping studies,
future research is needed to generate evidence of how and when to adjust for measurement error
in mapping.
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Future research should concentrate on developing more flexible unidirectional response mapping
models. Incorporating some of the features of the multidirectional mapping model developed here is
one possible direction but others should also be explored.
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Chapter 1 Introduction
In many health-care systems across the globe, decisions about the types of health technologies,strategies and service delivery options provided are informed by some form of economic evaluation.
This entails making comparisons between competing options in terms of their costs and benefits. The
type of economic evaluation in most widespread use is referred to as cost-effectiveness analysis (CEA).
In particular, health benefits are expressed as quality-adjusted life-years (QALYs). The QALY is a metric
that combines concerns for both length of life and quality of life into a single numeraire. It does so by
rating health states on a scale anchored around the values of one (a year spent in full health) and zero
(states equivalent to death).
The value that any specific health state can take on this scale is limited to a maximum of one, but can
take negative values if it is considered to be so severe that it is deemed worse than being dead. These
health state valuations, sometimes referred to as health state utilities, can be estimated using many
different methods. They can also be estimated from different samples of respondents. For example,
there is significant debate about whether health state utilities should reflect the values of patients
with experience of the condition or the values of the general public. Each of these options leads to
different valuations of health states and are important areas of research, though they are not the
focus of this report.
Our aim is to present new research on a specific approach to estimating health state utilities that has
become increasingly prevalent in recent years. This is the approach referred to variously as ‘mapping’,
‘cross-walking’ or ‘transfer to utility’. We use the term ‘mapping’ throughout this report.
Mapping refers to a two-stage process to estimate the utilities for the health states required for a CEA.
In the first stage, the relationship between the health state utilities of interest and some set of explanatory
variables is estimated using data from a sample of patients with the same clinical condition but not
necessarily related to a study of the health technology that is the focus of the CEA.The explanatory
variables may be some form of clinical measure, patient-reported outcome measures (PROMs) or other
sociodemographic information. In the second stage, the estimated model is used to predict the health state
utilities for health states required in the cost-effectiveness model.
This report provides more detail of what mapping is, how it has been performed previously and the
challenges that are faced when conducting a mapping study (see Chapter 2). In Chapter 3 we introduce
a series of flexible statistical methods for mapping that are designed to overcome many of these
challenges. We describe how they can be used and how the results from different model types can be
compared in a meaningful way. Chapter 4 presents results from a series of case studies that test and
compare the performance of different mapping models as well as a separate case study of the specific
case of mapping between two preference-based measures (PBMs). In Chapter 5 we present some
preliminary analyses on a number of methodological issues that we have identified in the course of our
research. Finally, we summarise our overall findings and provide recommendations for future research
based on those findings in Chapter 6.
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Chapter 2 Background
Preference-based measures
To calculate QALYs, there is a requirement not only to describe the impact of health technologies on
quality of life but also for that quality of life to be valued on the appropriate scale, that is, based on
the preferences of an appropriate sample and anchored around the values of one for full health and
zero for states equivalent to being dead.
One option for achieving this is to ask patients with the condition in question and experiencing the health
states that are relevant to the CEA to value their own health. The main methods for undertaking such
valuations take the form of thought experiments and are known as time trade-off (TTO) and standard
gamble (SG), though a range of other valuation methods can also be used, sometimes in combination. TTO
requires respondents to indicate the length of life in full health that they would consider equivalent to
some other length of life in their impaired state. They are therefore asked to directly trade off length of life
for improved quality of life. SG asks respondents to trade off uncertainty (between full health and death)
for health. Specifically, respondents are asked to choose between a certain option in impaired health and
an option associated with a return to full health with probability p, but also a risk of death with probability
1 – p.
However, these approaches are time-consuming to administer, relatively costly and place a substantial
burden on both study participants and researchers. In the context of a clinical study, these approaches
would often be considered not feasible. In addition to these practical constraints on direct utility elicitation,
the prevailing view of most health technology assessment (HTA) agencies is that the preferences of the
general public, rather than of patients only, are those most appropriate for informing investment decisions
in a publicly funded health-care system. Instead of obtaining values directly from patients, the values for
health states that are then used to calculate QALYs predominantly come from generic PBMs, which are
based on the preferences of some sample of the general public.
Most PBMs are intended to be applicable to a wide range of different disease areas and health
technologies and hence are termed ‘generic’. These measures have become core features of the
standard approach to measuring and valuing health and key inputs to the calculation of QALYs. A PBM
comprises two elements: a survey instrument that is used to describe health and a valuation set that
provides an ‘off-the-shelf’ set of values for each of the health states that can be described by the
survey instrument. These sets of values have been calculated using methods consistent with economic
theory, such as TTO and SG, in large scale samples of the general population. Thus, the practical
difficulties associated with the administration of these methods in patient samples are avoided.
Several such generic PBM instruments have been developed. The most widely used examples are the
EuroQoL-5 Dimensions (EQ-5D),1 of which there are two main versions [the EuroQoL-5 Dimensions,
three-level version (EQ-5D-3L), and the EuroQoL-5 Dimensions, five-level version (EQ-5D-5L)]; the
Short Form questionnaire-6 Dimensions (SF-6D),2 which is based on the Short Form questionnaire-36
items (SF-36);3 and the eight-dimensional Health Utility Index Mark 3 (HUI3).4 Table 1 summarises
these example measures.
Both the health classification systems and the response samples and analytical methods that underpin
the valuation sets differ for each of these PBMs. Effectively, this means that PBMs cannot be treated
as if they were interchangeable: they do not generate the same values for the same health states.9–14
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This has important implications for policy-makers seeking consistency across the health-care allocation
decisions they are required to make.
The EQ-5D-3L is one of the most widely used PBMs and can be used to illustrate how PBMs are
constructed and used. Its descriptive system comprises five dimensions: mobility, self-care, usual
activities, pain/discomfort and anxiety/depression. Respondents are asked to indicate their health
status on each dimension at one of three levels: no problems, some problems and extreme problems.
In total, 243 different health states can be specified by this descriptive system.5 In the UK, the values
attached to these health states range from –0.594 for the worst health state (extreme problems in all
dimensions) to 1 for full health (no problems in any dimension). Values for 42 of the 243 health states
were elicited using TTO from a final sample of 3395 UK members of the general public.5 To obtain
values for all health states described by the EQ-5D-3L, a regression model was used on these data to
estimate the value of all 243 health states.
Many jurisdictions recommend the use of PBMs for economic evaluation, such as those of England
and Wales,15 Spain,16 France,17 Thailand,18 Finland,19 Sweden,20 Poland,21 New Zealand,22 Canada,23
Colombia24 and the Netherlands.25 Some recommend the use of a specific instrument, usually the
EQ-5D.26
To use PBMs to facilitate the estimation of QALYs for CEA, the ideal situation in many cases would see
the PBM administered to patients as a PROM, at multiple time points, in clinical studies of the health
technology of interest. The patient responses to the descriptive system of the PBM would then be
attached to the pre-existing, off-the-shelf values by the analyst, who would calculate the health gain,
in QALY terms, associated with the health technology compared with the alternative treatment in the
clinical study.
However, there are many settings where either this ideal situation does not exist or it is insufficient for
the needs of the economic analysis. First, there may have been no PBM administered as part of the
relevant clinical studies. PBMs are largely required for the economic analysis, yet in many situations
the design of clinical studies focuses exclusively on establishing clinical effectiveness. Although HTA
agencies may increasingly encourage the use of PBMs, the impact of this varies and it is only one of
many different considerations for those funding and designing clinical studies. Second, there may have
TABLE 1 Key features of commonly used PBMs
Instrument Dimensions Levels
Number
of health
states
Valuation
method
Range of
health
utilitiesa
EQ-5D-3L Five dimensions: mobility, self-care,
usual activities, pain/discomfort and
anxiety/depression
Three levels: no/
some/extreme
problems
243 TTO –0.594 to 1
EQ-5D-5L Five dimensions: mobility, self-care,
usual activities, pain/discomfort and
anxiety/depression
Five levels: no/slight/
moderate/severe/
extreme problems
3125 TTO/DCE –0.285 to 1
SF-6D Six dimensions: physical functioning,
role limitations, social functioning,
pain, mental health and vitality
Between four and
six levels in each
dimension
18,000 SG 0.301 to 1
HUI3 Eight dimensions: vision, hearing,
speech, ambulation, dexterity,
emotion, cognition and pain
Between five and
six levels in each
dimension
972,000 SG and VAS –0.359 to 1
DCE, discrete choice experiment; VAS, visual analogue scale.
a The following value sets are used: EQ-5D-3L UK valuation;5 EQ-5D-5L England valuation;6 SF-6D Brazier et al.;7
and HUI3.8
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been a PBM administered in the relevant clinical studies but it is not the one that is recommended
for the jurisdiction in which the economic evaluation is to be undertaken. This frequently occurs in
cases of multinational clinical studies in which decisions about which PBM may be taken is based on
judgements about the needs of the countries in which the clinical study is taking place, or commercial
judgements about the most important markets. It can also be the case that, as new versions of PBMs
are developed, the HTA agency recommendations change. Third, although the appropriate PBM may
have been administered in clinical studies, this may be insufficient for the needs of the economic
evaluation. Often, economic models are required to extrapolate the differences in costs and benefits
beyond the limited time horizon of the clinical study, and/or to different populations. There may be
several studies that need to be combined, and multiple comparators not included in the key studies
need to be modelled. The clinical studies may not provide sufficiently large patient samples, patients
may be healthier than patients in real clinical practice and there may be few observations of rare but
important adverse events of disease complications. All of these factors mean that there is insufficient
information on health utilities from the clinical studies.
In all of these cases there is a deficiency in the evidence base that makes it insufficient to furnish the
requirements of the economic evaluation. ‘Mapping’ is one method that can be used to try to overcome
this deficiency.
Mapping: what is it and why is it used?
Mapping, also referred to as ‘cross-walking’ or ‘transfer to utility’,27 is a method used to predict what
the value of a health state would have been, perhaps conditional on many other factors, had it been
recorded directly with the PBM of choice. Mapping requires the identification of a suitable external
reference data set (meaning a different data set to the clinical studies that are deficient in some way)
that contains both the PBM required for the economic evaluation and the measure(s) that have been
used in the clinical study or that otherwise define the health states of interest.
The data from the mapping data set can then be used to estimate the relationship between the
PBM and the clinical outcome measures, thereby providing the means to bridge the gap between
the evidence available in the clinical studies and the requirements of the economic evaluation. The
mapping is used to impute the utility of health states from non-utility-based information about those
health states. Note that the mapping data set does not need to be from a study of the technology in
question, nor does it need to be derived from a randomised clinical study, because the mapping
estimation itself does not entail the estimation of a treatment effect.
The estimated statistical relationship may then be used to infer the missing PBM in the clinical study
so that it can be incorporated in the economic evaluation. If y denotes health utility and x the vector of
conditioning variables used in the mapping model (for example, the clinical outcome measure age or
gender), the estimated mapping model gives us an estimate of the conditional distribution of the
utilities, f(y|x). We can use the mapping model to do either of the below:
1. Simulate the distribution of utilities across patients using the full conditional distribution, f(y|x).
This use could be appropriate for a patient-based simulation model, or an economic evaluation
alongside a clinical trial, where the analyst needs to use the full distribution of patient utilities.
2. Predict the missing utility using the conditional expectation, E(y|x), as would be required for a
typical cohort-based decision model.
These two alternative uses of the mapping model are related to important concepts often confused in
the mapping literature. The unconditional distribution of utilities across patients, f(y), describes the
distribution of health state utilities. This distribution is bounded at the top by one, the value of full
health, and at the bottom by the lowest utility value for the particular instrument used (see Table 1).
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For a given set of conditioning variables, x = X, the conditional distribution, f(y|X), describes the
distribution of utilities in the subpopulation of patients for whom the conditioning variables take the
combination of values X; individuals with the same observable characteristics X differ in their observed
utilities owing to an unobserved random component. The conditional expectation, E(y|X), is the mean
of the conditional distribution, f(y|X); individuals with the same observable characteristics X share the
same mean. Therefore, the variation in the distribution of the conditional means, E(y|X), is due to the
variation in the combinations of values X in the population of interest. The conditional distribution,
f(y|x), includes, in addition, the unexplained variation of utility around the conditional means. Hence,
the distribution of the conditional means differs from the conditional distribution. In particular, the
distribution of the conditional means will always have less variation than the conditional distribution.28
We outline this issue in more detail in Chapter 3, Predictions: mean versus distribution. It is worth noting
at this point that estimating the entire conditional probability structure, f(y|X), has the advantage of
allowing the mapping model to be used for both (1) and (2) above, as the conditional means can be
derived from it.
Mapping is in widespread use in HTA. A database of mapping studies updated in 2019 [Health Economics
Research Centre (HERC) database of mapping studies]29 contains 182 published studies. Many more are
undertaken for specific economic evaluations but are never separately published. A review of 79 National
Institute for Health and Care Excellence (NICE) appraisals in 201330 found that 22% were reliant on
mapping, either from published sources or mapping estimated specifically for the appraisal.
Mapping is an area in which guidance on some specific areas of good practice has been published,
intended to reflect existing research evidence31,32 or provide recommendations on reporting standards.33
Overview of different mapping approaches
There is a longer history of studies examining alternative statistical models for cost data in the
published literature than health utility data.34,35 Cost data are characterised by non-negative values,
heteroscedasticity and high kurtosis because of large proportions of respondents incurring zero costs
(the lower limit). Much less attention has been given to the challenges associated with modelling health
utility data until more recently. This is surprising for two reasons. First, the challenges associated with
utility data are more numerous than those associated with costs. Second, the incremental benefits
appear in the denominator of the incremental cost-effectiveness ratio (ICER) and are typically very
small, such that apparently trivial changes arising from differences in estimation methods often lead
to far from trivial differences in estimates of cost-effectiveness.
In general terms, there are two types of methods for mapping. The first is a one-step process that
models the health utility values directly. Although potentially simpler, this means that the resultant
mapping model is specific to the value set for which the model was estimated; it cannot be used for
other countries where a different value set is relevant. This approach also discards the more detailed
information contained in the responses to the individual dimensions. In some cases, this information
may be quite useful.
The second set of mapping methods can be labelled as indirect mapping approaches (also referred to
as ‘response mapping’), which use a two-step process. In the first step, the discrete responses to the
descriptive system of the instrument are modelled. For example, in cases in which the EQ-5D-3L is
the target of the mapping model, five (typically independent) discrete data models (such as ordered
probits/logits, multinomial logits) are used. The models estimate the probability of the health state
of the individual being at levels one, two and three for each dimension in the descriptive system.
Once these models have been estimated, they can be used to calculate the expected health utility
as a second, separate step, using the estimated distribution of responses together with a value set.
Because it is only the second step that is value-set specific, the same first-stage mapping model can
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be used for any country. However, the indirect approach also needs enough responses at all levels
in each dimension, otherwise the mapping model is unable to predict a full conditional probability
distribution across all health states. Mappings to PBMs with a larger number of levels in each
dimension are more likely to encounter this problem.36,37
Direct methods
Modelling health utilities directly is not straightforward because such data are characterised by several
challenging features. Health utility data are bounded: limited at the top at one (the value of full health)
and at the bottom by the value of the worst health state described by the instrument. The location of
this lower boundary differs by PBM and by the country-specific value set, but they all must have a
lower bound (see Table 1). Most data sets exhibit a significant mass of observations at the upper
boundary of one, immediately followed below by a relatively large gap in the distribution before the
next feasible utility value. The rest of the distribution is usually characterised by multimodality and/or
skewness. The degree to which these features are apparent varies by instrument, disease area and
patient sample severity.
Given these distributional features, it is perhaps surprising to find the widespread use of linear regression
for mapping. The HERC database29 reports the first identified mapping study as using a linear regression
for modelling the relationship between EQ-5D-3L and other disease-specific outcome measures in a
sample of patients with rheumatoid arthritis (RA).38 Linear regressions are the most commonly used
direct mapping model, usually estimated using ordinary least squares (OLS), with a smaller number of
more recent studies using robust MM estimators (the MM estimators is a class of robust estimators for
the linear model introduced by Yohai39). A recent systematic review of mapping studies to PBMs found
that linear regression estimated using OLS was still the most common approach, used at least 75% of the
time in each of the PBMs covered in the review.40
Modelling PBMs using a linear regression is problematic because of the features that are typical of
health utility data.
The first issue, which has received surprisingly little attention in this area, relates to the bounded
nature of PBMs. Linear regression is built on the assumption that the regression function is linear.
In other words, the expected value of health utility, conditional on a predictor variable, looks like a
straight line when plotted against the value of the predictor variable. Figure 1 shows why that linearity
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FIGURE 1 Example of incorrect prediction by misspecified linear regression for health utilities limited at 1.
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assumption causes problems for regression prediction. As health utility can never exceed one, its expected
value conditional on the predictor x can also never exceed one. It will generally lie below one and approach
it as an asymptote as x increases (assuming x and y are positively related). Thus, the true regression
relationship (the solid red line in Figure 1) must be non-linear in general. Mistakenly fitting a straight line
(the dashed blue line in Figure 1) then tends to overpredict health utility for cases with health utility
likely to be at or close to one. Linear regression will also tend to underpredict health utility in cases of
very poor health, because the slope of the regression line is too large.
A possible response to this problem would be to use non-linear regression – in other words, fit a curve
like the solid curve (solid red line) in Figure 1. This type of regression is robust in the sense that it
gives approximately unbiased estimates even if the usual assumption of normally distributed and
constant-variance residuals are invalid. Unbiasedness requires that the non-linear form fitted is linear
in parameters; if this is not so, the non-linear regression estimator is consistent rather than unbiased,
and gives good results in large samples (subject to mild regularity conditions). However, some of the
standard inferences about the model [hypothesis tests, confidence intervals (CIs), etc.] will be invalid
unless the constant-variance (homoskedasticity) assumption is correct. Unfortunately, a limited dependent
variable model cannot have a constant residual variance: as the regression curve approaches the ceiling of
one, the variance must decline towards zero, as illustrated in Figure 1. In any case, even if homoskedasticity
were a tenable assumption, standard tests and CI formulas may be poor approximations in small
samples, given the non-normal features of skewness, discontinuity and multimodality that characterise
health utility data.
Published evidence repeatedly demonstrates the poor performance of the linear regression. Most studies
illustrate this with reference to the conditional means and show that the models tend to understimate
mean health utility at the upper end of the distribution, where patients are in good health, and
overestimate it at the bottom end, where patients are in poorer health as expected given the discussion
above. Chapter 3, Model comparisons, illustrates with an example the type of systematic underpredictions
and overpredictions that one is likely to see when using linear regressions as opposed to other models
that can account for all of the features of the data.
In cost-effectiveness models that assess the value of clinically-effective treatments, the use of these
mapping models will bias results. They tend to underestimate the true value of health gain, resulting in
lower QALYs and higher cost-effectiveness ratios. Even though the magnitude of the bias seems small,
it is large relative to the range of PBMs, and, in economic models, those biases accumulate over the
individual’s lifetime. Furthermore, cost-effectiveness ratios are unstable quantities usually portraying
large numbers on the nummerator divided by very small numbers. Small changes to the denominator
typically result in large changes in the cost-effectiveness ratio that have the potential to change
reimbursement decisions solely because of the mapping model used.41 Alternative models have been
considered, on the basis that they may be more suitable to some aspects of the utility distibution. For
example, tobit, censored least absolute deviation and two-part models had been used in the literature
to capture the large proportion of observations at full health.
The use of the tobit model in mapping has been subject to discussion in published literature in relation
to its potential appropriateness or otherwise for health utility data. In particular, it has been argued
that the tobit model is inappropriate for modellig health utility data because it is designed for the
analysis of censored data: health utility data are not censored because values of health > 1 are not
possible.42 This criticism stems from an apparent confusion between two different applications of the
tobit model that lead to the same statistical model. The tobit model can arise from true data censoring
where the variable of interest is not fully observed. It is in the context of data censoring that the tobit
model is most typically used in economics at present. A typical example of this is modelling data on
income using data from surveys that, to encourage responses at higher levels of income, use an upper
limit above which respondents need to indicate only if their income is above that limit. The data are
thus observed to lie within a particular range only, which causes a pile-up of observations in that
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category. However, the variable of interest is still underlying income. The same tobit model can also
arise from a corner solution of choice, as in Tobin’s original article.43 Tobin developed his original model
to deal with variables that are limited, not censored, such as expenditure on durable goods. Expenditure
can only be positive or zero, and the variable is referred to as limited at zero. At very disaggregated
levels of expenditure or for luxury goods, pile-ups at the ‘corner’ of zero are likely. There is no censoring
in this case; the entire range of the variable is observed. In fact, the word ‘censored’ is completely absent
from Tobin’s original paper. Health utility data are analogous to this second case. The variable of interest
is the actual response variable and the pile-up at one represents a corner solution. This distinction is
important for prediction purposes. The linear prediction is appropriate if the pile-up is due to censoring,
but the (non-linear) prediction of the response variable should be used in the case of a corner solution.
The range of alternative methods, including the use of the tobit model, have tended to not improve
over the poor fit of the linear regression. This is because these methods address only some of the
challenging distributional features of health utility data. Only models that are able to address all
features are true contenders for a properly specified mapping model. Worryingly, this has led to
a widespread claim that mapping is fundamentally unreliable.44 This belief has been shown to be
misguided with the application of more flexible statistical methods in many studies. Austin and
Escobar45 proposed the use of finite mixture models to estimate PBMs and applied it to the HUI3.
Mixtures of normal distributions are very flexible and can approximate functional forms that are
difficult to model using a single distribution. Their use is often linked to the presence of multimodality,
but they can also approximate unimodal, highly skewed or kurtotic distributions. Austin and Escobar45
use a degenerate normal distribution with a mean of one and a very small standard deviation to
account for the mass of observations at one. Mixtures of normal distributions have been used to
model other PBMs, such as the EQ-5D-3L,46–49 SF-6D46 and HUI3.48 Hernández Alava et al.50 introduced
a finite mixture model specifically developed to deal with the idiosyncracies of EQ-5D-3L data. The
model is based on underlying distributions analogous to the tobit model (corner solution), extended to
allow for the gap between one and the immediately previous value encountered in health utility data.
The model has been applied successfully to different disease areas51–54 as well as different PBMs.37
Simultaneously, a separate strand of the methodological literature introduced the use of beta
distributions. Beta distributions are very useful for modelling health utilities data because they are
bounded and are able to accommodate a number of different shapes. Similarly, fractional response
models are very useful in modelling bounded data, but, unlike models based on beta distributions,
provide only estimates of the conditional means, not the conditional distribution of utilities. Basu and
Manca55 proposed the use of two-part beta regressions to account for bounded data, skewness and the
spike of observations at the value of full health. Some studies have suggested that beta regression is
not appropriate in cases where the PBM displays negative values56 and, in some cases, researchers
have converted all negative values to zero ad hoc purely for convenience,57,58 inadvertently creating a
potential problem given the sensitivity of beta regressions to observations at the boundaries. Standard
transformations exist and are regularly used with beta regressions in other applications.59 The beta
regression approach has been extended to the use of mixtures.47 The development of methods based
on beta mixtures is described further in Chapter 3, Flexible modelling methods for mapping, Direct
methods: the beta mixture model.
Indirect methods
Fewer applications of indirect methods have been documented, which may be because of the
requirement for data that spans all response categories. The first reported indirect mapping model we
are aware of comprised a set of independent multinomial logit models.60 Gray et al.61 also estimated a
set of independent logit models and coined the term ‘response mapping’, which has been adopted more
widely. This approach reflects the two-stage data generating process of health state data: it separates
the modelling of the responses that individuals give using the descriptive system of a quality of life
instrument from the valuations of those health states.
DOI: 10.3310/hta24340 Health Technology Assessment 2020 Vol. 24 No. 34
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Hernández Alava et al. under the terms of a commissioning contract issued by the Secretary
of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be
included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for
commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha
House, University of Southampton Science Park, Southampton SO16 7NS, UK.
9
Response mapping methods have been developed to use models that reflect the ordered nature of
the response data using ordered probits/logits and generalised ordered probits.51,53,62 Others relax
the independence assumption through the use of multivariate ordered probits.63 The multivariate
model was shown to outperform competing independent dimensions models and set the ground for
future avenues of research in the indirect mapping literature. However, estimating models involving
high-dimensional ordinal variables remains an onerous task. The development of methods based on
response mapping is described in Chapter 3, Flexible modelling methods for mapping, Indirect methods:
systems of ordinal regressions using copulas.
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Chapter 3 Development of methods
for mapping
The characteristics of PBM data (bounded, with large numbers of observations at one boundary;non-standard distributions with gaps) as well as the small number of covariates often available for
statistical modelling mean that flexible models are often required to avoid biases in the parameter
estimates. This chapter summarises some of the methodological developments achieved during this
project, concentrating specifically on the development of appropriate models for mapping and
examining issues around model comparisons. Additional methodological developments are left to
Chapter 5, in which a number of issues not directly related to model development are presented.
Flexible modelling methods for mapping describes two new flexible statistical models. Although they have
been developed specifically for mapping, they can be applied outside this area in cases in which flexible
models are needed. Predictions: mean versus distribution clarifies concepts often confused in the mapping
literature and that have sometimes been used to dismiss mapping as a useful approach. These concepts
are not exclusive to mapping; they apply equally to any statistical model. Model comparisons presents
some graphical approaches to comparing mapping models to aid model selection. The advantage of
these graphical approaches is that they have been designed with awareness of the role of mapping as
an input into cost-effectiveness analyses.
Flexible modelling methods for mapping
Two mapping models, one based on the direct approach and one based on the indirect approach, were
developed during this project to provide researchers with alternative flexible models when mapping.
The direct model is based on finite mixture distributions that have already been shown to be successful
in this area. It is similar to the adjusted limited dependent variable mixture model (ALDVMM),50 a model
developed specifically for mapping that replaces the underlying normal distributions with beta distributions.
One potential advantage of the beta distribution over the normal distribution is that its range is limited and
can, therefore, easily accommodate variables such as PBMs, which have natural boundaries, although
problems arise when there are large numbers of observations at those boundaries. A second potential
advantage relates to the variety of shapes that it can generate with a single distribution, in contrast to the
bell shape of the normal distribution. The model is briefly presented in Direct methods: the beta mixture model.
In most cases, mapping is unidirectional; we are interested in converting one measure to another, for
example a disease-specific measure to a PBM, but not the other way around. The indirect model
presented in this chapter (see Indirect methods: systems of ordinal regressions using copulas) has been
specifically developed for cases in which the mapping model might need to be used multidirectionally.
It was designed specifically for the case of mapping between two similar PBMs, EQ-5D-3L and EQ-5D-5L,
but the general statistical model can be applied to other measures and extended to more than two PBMs.
It is a multiequation model of ordinal regressions estimated jointly using copulas to capture the
dependencies between the EQ-5D-3L and EQ-5D-5L dimensions. It also incorporates finite mixtures
to allow for non-normality of the errors. The model is more challenging to estimate than unidirectional
models and this complexity is not necessary for more standard uses of mapping.
Direct methods: the beta mixture model
The beta mixture model is described fully in a paper describing betamix,64 a Stata® versions 14 and
15 (StataCorp LP, College Station, TX, USA) community-contributed command developed to facilitate
estimation of this model; its first application in the mapping literature can be found in Gray et al.37
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The following sections give some important background information about mixture models before
summarising the beta mixture model.
Mixture models: background
Finite mixture models provide a very flexible statistical framework. Instead of assuming that a single
distribution is enough to model a dependent variable, a number of individual component distributions
are used. These distributions are mixed according to a probability structure.65 Mixture models arise
naturally when there is discrete heterogeneity in the population because the different mixture
components (also known as classes) can be used to represent the different groups in the population.
Although finite mixtures tend to be introduced in this context, they have another important use.
Because any continuous distribution can be approximated by a finite mixture of normal densities,
mixture models provide a convenient semiparametric framework to model distributional shapes that
cannot be easily accommodated by standard distributions. They are parametric because each of the
component distributions have a parametric form but have nonparametric features as the number of
individual components is allowed to increase. Therefore, they possess a lot of the flexibility associated
with nonparametric approaches as well as maintaining some of the benefits of parametric models.
This flexibility is the key to their usefulness for direct modelling approaches in the mapping literature.
Mixture distributions are often used when distributions are multimodal as a way of capturing this
feature, but it is important to understand that they can also approximate other features such as
skewness, kurtosis and heteroscedasticity. Figure 2 illustrates the different shapes a mixture can
take using a simple example of only two equal variance components. Figure 2a shows two normal
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FIGURE 2 Examples of mixtures of two normal components with equal variance (σ2= 1) and mean of the first component
(µ1= 0). (a) Mean µ2 = 2, mixing probability pi = 0.5; (b) mean µ2 = 4, mixing probability pi = 0.5; (c) mean µ2 = 2, mixing
probabilities pi1= 0.75 and pi2= 0.25; and (d) mean µ2 = 4, mixing probabilities pi1 = 0.75 and pi2 = 0.25. (continued )
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components of variance equal to one. The first component has a mean of zero, the second component is
located towards its right with a mean of two and they are mixed with equal probabilities. This produces a
wide distribution with a flat top. Figure 2b differs in that the second component is now moved further to
the right, having a mean of four. By allowing for a relatively larger separation between the components,
a bimodal distribution is produced. Figures 2c and 2d depict the same two distributions used in Figures 2a
and 2b respectively, but now the components are mixed with different probabilities. Component one has
a probability of 0.75 and the second component a probability of 0.25. The wide and top flat distribution
of Figure 2a turns into a skewed distribution in Figure 2c, whereas the bimodal distribution in Figure 2b
is still bimodal but the modes have a different height in Figure 2d. An even larger number of shapes can
be generated by also allowing the variances of the distributions to differ and by increasing the number
of components.
It is important to stress that the presence of two modes in a distribution does not imply that exactly
two components are needed. We modelled conditional distributions, and some bimodality of the
conditional distribution may be accommodated by the conditioning variables. In the case of mapping,
the number of conditioning variables is typically small and, in our experience, not large enough to
accommodate the extreme bimodality arising from the value set present in, for example, EQ-5D-3L UK
utilities. In addition, it might be the case that more than two components are needed to accommodate
a bimodal distribution if, for example, the two modes are also skewed. In such circumstances, we might
need two or more components to accommodate this shape per mode in the distribution, which implies
that four or more components are needed to model the distribution successfully.
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FIGURE 2 Examples of mixtures of two normal components with equal variance (σ2= 1) and mean of the first component
(µ1 = 0). (a) Mean µ2 = 2, mixing probability pi = 0.5; (b) mean µ2 = 4, mixing probability pi = 0.5; (c) mean µ2= 2, mixing
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It is also important to note that a mixture model is not the same as a piecewise model. The latter has
also been used in mapping and splits the dependent variable in fixed ad hoc intervals and then assumes
a different model distribution in each part.49
The flexibility of mixture distributions comes at the cost of more involved estimation. The analyst
needs to make judgements about (1) where to include the conditioning variables and (2) the number
of components. Conditioning variables might affect the mean of each component or the probability of
component membership or both. In addition, choosing the appropriate number of components involves
estimating models with increasingly larger numbers of components until an acceptable model has been
found. Thus, a considerable number of possible models need to be thoroughly investigated. There are
practical challenges associated with fitting mixture models estimated using maximum likelihood. One of
the problems relates to the presence of several local maxima in the likelihood function. Convergence
to a solution does not imply that the consistent solution has been found because the optimisation
algorithm could have converged to a local maximum. To identify the global maximum one can use a
global optimisation algorithm such as simulated annealing. However, global optimisation algorithms
are slow in comparison. Alternatively, the model can be estimated using a large number of random
starting values and selecting the model with the largest likelihood. Both methods have advantages and
disadvantages. A second problem arises when estimating mixture models of normal distributions with
different component variances. In such circumstances, the likelihood becomes unbounded as the
variance of one of the components tends to zero. As Aitkin points out, this is not a ‘real’ problem;66
it arises because the normal distribution cannot represent the likelihood when the variance tends to
zero. Essentially, the component becomes a probability mass but the likelihood contribution of the
density of that component becomes infinite. Provided that certain regularity conditions are met, the
consistent solution will correspond to a local maximiser.65
The first mixture model developed specifically to deal with the idiosyncrasies of PBMs was the
ALDVMM.50 The model was based on mixtures of densities similar to those underlying the tobit
model but allowing for a gap between one (full health) and the next value in the PBM. It was originally
developed with the characteristics of the EQ-5D-3L UK value set in mind. Here, we have generalised
the ALDVMM to accommodate the boundaries of any PBMs. The model is also able to reflect the gap
between full health and the next feasible health state, according to the characteristics of whichever
PBM or value set is of interest, and has the additional option of not reflecting any gap at all but treating
the distribution as continuous between the upper and lower bounds. All of these developments are
encompassed in the freely available Stata command ALDVMM.67
The beta mixture model
The development of the beta mixture model followed from, on the one hand, the proven advantages
of the ALDVMM in modelling EQ-5D-3L and, on the other hand, the development in a different strand
of the literature of models based on the beta distribution.55 The beta distribution is very convenient
when it comes to modelling PBMs; it is a bounded distribution, as are all PBMs, and can accommodate
a number of different shapes: by varying its mean and precision parameter, the distribution can be
symmetric or asymmetric and bell-, J-, or U-shaped. Although the beta distribution is bounded in the
interval (0,1), a standard transformation can be used to change its support to any finite interval such
as those covered by different PBMs. The disadvantage of the beta distribution is that the boundaries
are outside its region of support. In some cases, a small amount of noise is added to the observations
on the boundary to pull them inside the support region. This solution can work but only as long as
the number of observations on the boundaries is relatively small. It has been shown that the beta
distribution is very sensitive to large numbers of observations at the boundaries59 and the solution
above might severely distort the distribution. In those cases, one can mechanically add mass points at
the boundaries, but the problem then lies in the interpretation of these probability masses. In some
cases it might be easy to justify the presence of a separate mass point on the boundary, but in other
cases it is mere statistical convenience.
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Although the beta distribution can take many shapes, bimodality is one characteristic that it cannot
reproduce. It follows that augmenting the model with mixtures provides additional flexibility as well as
the ability to cope with multimodality. In the area of mapping, mixtures of beta regressions have been
used to model EQ-5D-3L.47 We modify the standard mixture model to account for the gap between
full health and the next feasible values as well as allowing for different approaches to model the
observations on the boundaries. Details of the model are presented in full in Gray et al.64 The model
structure is presented here briefly.
It is assumed that utility for individual i, yi, is defined at full health (1) and in the interval [τ, b], with
τ denoting the highest utility value below full health and τ > b. The conditional density of yi can be
written as:
g(yijx1i, x2i, x3i) =
P(yi = 1jx3i) if y i = 1
P(y i = τjx3i) if yi = τ
P(y i = bjx3i) if y i = b
1− ∑
s=1,τ,b
P(y i = sjx3i)
" #
h(yijx1i, x2i) if yi∈(τ, b),
8>>>>><
>>>>>:
(1)
where x1i, x2i, x3i are vectors of covariates affecting the mean of each component, the probabilities of
component membership and the probability of a boundary value, respectively. The probabilities P(yi|xi3)
are defined using the following multinomial logit model:
P(y i = kjxi3) =
exp(x′i3γk)
1 +∑
s=a,τ,b
exp(x′i3γs)
for k = 1, τ, b, (2)
where γk are the vectors of corresponding coefficients. The probability density function h(.) is a mixture
of C-component beta distributions:
h(yijx1i, x2i) = ∑
c
c=1
n
P(cjx2i)
Γ(ϕc)(y i−1)
(µci − 1
τ−1 )ϕc −1(τ− yi)
(τ− µci
τ−1 )ϕc −1
Γ
µci −1
τ−1
 
ϕc
 
Γ

τ− µci
τ−1

ϕc

(τ−1)ϕc −1
o
, (3)
with
µci(x1i; βc) = 1 + (b−1)
exp(x′1iβc)
1 + exp(x′1i βc)
, (4)
and the probability of latent class membership defined by a multinomial logit model with coefficients δc:
P(cjx2i) =
exp(x′i2δc)
1 +∑C
j=1
exp(x′i2δ j)
. (5)
The likelihood of this particular beta mixture model is given by:
ln l(γ, β, δ,ϕ) = ∑
i:yi=1
ln P(yi = 1jx3i, γ) + ∑
i:yi=τ
ln P(y i = τjx3i, γ) + ∑
i:yi=b
ln P(y i = bjx3i, γ)
+ ∑
i:yi∈(τ,b)
ln
(
1− ∑
s=1,τ,b
P(y i = sjx3i, γ)
)
+ ∑
i:yi∈(τ,b)
ln ∑
C
c=1
h(y ijx1i, x2i)
 
,
(6)
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Compared with the ALDVMM, this model generates observations at full health and those below using
two different processes (two-part model). The bounded nature of the data are handled naturally by a
bounded distribution. These boundaries are b, the lowest value for the PBM, and τ, the highest utility
value below full health, because the mass of observations at one is being handled by the other part
of the model. However, values on the boundary create a problem for this distribution, which cannot
handle them without further adjustment. Small numbers of observations at the boundaries (the lowest
health state value and the value of the health state immediately below full health) can usually be
handled by adding a small amount of noise to those observations so that they fall just inside the
boundaries. However, a substantial amount of observations at the boundaries needs to be handled by
adding a mass point at either or both of the boundaries to avoid distortion. Although this adaptation
makes the approach appropriate for the features of the typical health utility distribution, it will
increase the number of model parameters. By contrast, ad hoc mass points are not necessary when
using the ALDVMM because observations can be generated at those boundary values.
Indirect methods: systems of ordinal regressions using copulas
As research and our understanding of PBMs progresses, it is inevitable that new versions of PBMs are
developed. Concerns regarding the lack of sensitivity of the three-level version of the EQ-5D and the
usual pile-ups of observations at full health owing to its coarse structure led to the development of a
new five-level version: the EQ-5D-5L. The model introduced here was developed specifically for the
purpose of testing the consistency between the responses to the EQ-5D-3L and EQ-5D-5L and to
assess the likely impacts for economic evaluation of moving from the original three-level version to the
newer five-level version. The NICE methods guide that was published in 201315 suggests that either
version of the EQ-5D could be used in appraisal submissions once a valuation set for the EQ-5D-5L
became available. However, the consequences of using different versions of the EQ-5D could not be
explored until a preliminary version of the EQ-5D-5L valuation was published in 2016,68 with a final
version published in 2018.6
The standard mapping case needs to be performed in only one direction, mapping from some set
of clinical or other non-PBMs to the PBM of interest. In this case, to examine the similarities and
differences between the different versions of the EQ-5D, mapping needs to be bidirectional, permitting
the analyst to map from the EQ-5D-3L to EQ-5D-5L and vice versa in a consistent way. This consistency
cannot be achieved by estimating two separate models, one for each direction, because this ignores the
relationships between the parameters in both models.
The aim is to test the hypothesis that the three-level and five-level versions of the EQ-5D instrument
are mutually consistent descriptors of health states and, consequently, can be used interchangeably.
The model needs to be as flexible as possible to avoid imposing unnecessary restrictions that could
lead to inconsistent estimates. Several important features are introduced that build on more basic
indirect mapping models described in Chapter 2, Overview of different mapping approaches, Indirect
methods. First, the model needs to map from the EQ-5D-3L to EQ-5D-5L and vice versa in a consistent
way. For this reason, we developed a joint model of the responses to 10 ordinal regressions (five for
each dimension of each EQ-5D version). Second, we allowed the structural parts of the model to
differ between the EQ-5D-3L to EQ-5D-5L so that we can test the assumption that EQ-5D-3L and
EQ-5D-5L share the same underlying concept but that the five-level version involves more detailed
categorisation. Third, the model captures the strong association between the same dimensions in the
three-level and five-level versions using a copula representation,69 thus allowing different strengths
of association across the health distribution and different patterns of association across the different
dimensions of the EQ-5D. Fourth, the assumption of normality underlying the ordinal equations
is generalised using two component normal mixtures (see Mixture models: background) to avoid
misspecification of the distribution of the errors, which could lead to inconsistent estimates.
Fifth, a random latent factor affecting all responses is introduced to reflect individual-specific
effects that will manifest as dependence across all dimensions in both EQ-5D versions.
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A full technical account of the model can be found in Hernández-Alava and Pudney70 and in the
associated Stata command, eq5dmap,71 which calculates predictions based on several estimated
mapping models. The command can predict from the EQ-5D-3L to EQ-5D-5L and vice versa using
either the individual-level responses or a mean utility value. The model is briefly summarised below.
The model is a system of 10 latent regressions arranged in five groups, one for each EQ-5D dimension
d as follows:
Y3d = Xβ3d + U3d
Y5d = Xβ5d + U5d
)
d = 1, : : :, 5 (7)
where X is a matrix of covariates, β3d and β5d are column vector of coefficients and U3d and U5d are
unobserved residuals, as detailed below. The observed variables Y3d and Y5d are generated by the
following threshold-crossing condition:
Ykd = q iff Γkqd ≤Y

kd < Γk(q+1)d, q = 1, : : :,Qk and k = 3, 5, (8)
where Qk = 3 or 5 is the number of EQ-5D levels and Γkqd are threshold parameters with Γk1d = –∞ and
Γk(Qk+1)d = +∞. The residual for individual, Ukid, is decomposed into an individual effect, Vi, which induces
correlations across the responses of an individual and a specific residual, εkid, correlated within
dimensions but not between:
Ukid = ψ kdV i + εkid, (9)
where ψkd is a set of 10 different parameters. We make the usual assumptions that, conditional on X,
Vi is independent of all εkid and all εkid are mutually independent, with the exception that within each
dimension d, ε3id and ε5id can be dependent. To allow for departures from normality, Vi and all εkids are
assumed to have a two-component finite mixture of normal distributions. The mixture for the errors εkid
is written as follows:
G(ε) = piΦ
ε− µ1
σ1
 
+ (1− pi)Φ
ε− µ2
σ2
 
, (10)
where pi is the mixing parameter; the location (µ1, µ2) and dispersion (σ1, σ2) parameters are constrained
to satisfy the usual mean and variance normalisations, which in the case of the mixture above are:
piµ1 + (1− pi)µ2 = 0 (11)
and:
pi(σ21 + µ
2
1) + (1− pi)(σ
2
2 + µ
2
2) = 1. (12)
The within-domain dependency between ε3id and ε5id is captured using a copula specification66 to derive
the joint distribution from the marginal distributions assumed. Copulas are very useful not only because
they can be used to derive difficult joint distributions from marginals but also because they can represent
a number of different dependence structures. The copulas we considered in the empirical application are
independent, Clayton, Gumbel, Frank and Joe. Figure 3 shows scatterplots of samples generated by Monte
Carlo simulation from three bivariate copulas, Gaussian, Frank and Clayton, all specified with a common
Kendall’s τ ≈ 0.7 to illustrate the copulas’ dependence patterns. The Gaussian and the Frank copulas can
exhibit positive and negative dependence, and the pattern of dependence is symmetric in both tails.
However, compared with the Gaussian copula, the Frank copula exhibits weaker dependence in the tails,
and dependence is strongest in the middle of the distribution. This is clearly seen in Figure 3, in which the
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FIGURE 3 Scatterplots of pseudorandom samples drawn from three different bivariate copulas. (a) Gaussian copula;
(b) Frank copula; and (c) Clayton copula.
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points on the tails of the Gaussian copula are closer together than those on the tails of the Frank copula.
However, in the middle of the distribution the points are closer together in the Frank copula than in the
Gaussian. By contrast, the Clayton, Gumbel and Joe copulas do not allow for negative dependence, and
dependence in the tails is asymmetric. The Clayton copula exhibits strong left-tail dependence (see Figure 3c,
in which the points on the left-hand side are close together) and relatively weak right-tail dependence.
Thus, if two variables are strongly correlated at low values but not so correlated at high values, then the
Clayton copula is a good choice. The Gumbel and Joe copulas display the opposite pattern, with weak
left-tail dependence and strong right-tail dependence. The right-tail dependence is stronger in the
Joe copula than in the Gumbel, and thus the Joe copula is closer to the opposite of the Clayton copula.
An additional Stata command, bicop,72 developed during this project, allows analysts to estimate a
simplified version of the model of the five bivariate ordinal regressions for each dimension separately.
This version of the model may be used in cases where the full multivariate model is not needed; it still
preserves the flexibility of the copulas for joining a pair of dimensions but does not allow for
correlations across dimensions.
Predictions: mean versus distribution
Little attention has been paid to how to interpret, assess and use the results from mapping studies in
economic evaluations. In particular, there has been confusion about methods for the reflection of
uncertainty and variability from mapping studies.
Some authors73–77 have stated that mapping underestimates uncertainty because the sample variance of
the data is always larger than the variance of the in-sample predictions. When using the expected value
to predict, the sample variance of the predictions will always be smaller than the variance of the sample
data because the mean predictor can only predict the variation in the utilities owing to the observed
covariates. If the economic evaluation requires only the mean utility, using the mean predictor presents
no problems because QALYs are a linear function of the profile of utilities over time. If, for some reason,
an estimator of the variance of utilities is needed, a consistent estimator can be obtained by calculating
the variance of the predictive distribution of the utilities as long as the mapping model is correctly
specified; the variance of the predictions is not an appropriate estimator and should not be used.51,70
The following sections illustrate these points using a simple case study, with data drawn from patients
with RA. In brief, the data are drawn from FORWARD (the National Databank for Rheumatic Diseases)78
and have been the subject of a detailed mapping study in which the data were fully described.51 A brief
description can be found in Chapter 4, Case study data set: FORWARD. Purely for the sake of simplicity, we
will consider a linear regression model that estimates health utilities using the EQ-5D-3L UK tariff as a
function of the Health Assessment Questionnaire (HAQ), which is a commonly used measure of functional
disability ranging from 0 (no functional disability) to 3 (maximum functional disability). In practice, there
are reasons why a linear regression is unlikely to be appropriate in this situation (see Chapter 2, Overview
of different mapping approaches, Direct methods), and additional covariates should be used.50,51 Everything
illustrated here applies equally to other model types, irrespective of the number of covariates and the
health utility values being used as the dependent variable.
Predictions from mapping models
Figure 4 provides a plot of the distribution of EQ-5D-3L (UK valuation) scores from all 100,398 observations
in the sample that have both EQ-5D-3L and HAQ data. It shows that the health utilities for individual
patients in the sample span the whole feasible range of the EQ-5D-3L: from –0.594 (the worst heath
state described by the EQ-5D-3L) to 1 (full health). The HAQ scores for these patients also vary: all the
way from the least degree of functional disability (0) to the maximum (3). It is also the case that in the
sample there are patients with the same level of HAQ but different levels of EQ-5D-3L.
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If we model the EQ-5D-3L using a simple linear regression with the HAQ as the sole explanatory
variable then we are assuming that, at the population level, there is a relationship between the
EQ-5D-3L and HAQ (the population regression line):
EQ5Di = α + βHAQi + εi, (13)
where the εi are independent and identically distributed error terms assumed (for simplicity) N(0,σ2) for
individual i. This model implies that, conditional on the HAQ, the EQ-5D-3L has a normal distribution
with mean:
E½EQ5DijHAQi = α + βHAQi, (14)
and variance:
Var½EQ5DijHAQi = σ
2 (15)
This means that one can never predict EQ-5D-3L values perfectly for every individual in the sample
using the mean predictor because, even if α and β were known with complete certainty, for each and
every value of the HAQ there is an entire distribution of values of the EQ-5D-3L in the population.
In the statistical model this is reflected by the presence of the latent variable ε, which, being random
itself, imparts randomness to the EQ-5D-3L. The latent variable ε exists at the population level. It does
not disappear as the sample tends to the population. In other words, the model reflects the fact that
individuals are different from each other. Not every person with the same HAQ value has the same
EQ-5D-3L value in the data or in the population and the statistical model does not assume that they
do. Indeed, individual-level data exhibit a much greater range of variation compared with aggregate-
level data. This is because there are many factors unique to individuals, such as their own tastes and
preferences, which cannot be observed. These factors are therefore included in ε, typically making σ2 a
large component of the variation in the dependent variable. This is one of the reasons why summary
measures of fit based on differences between the data and the predictions (an estimate of ε for the
individual), such as R2, mean absolute error (MAE) and root mean squared error (RMSE), are quite
insensitive to model specification changes (see Model comparisons).
To expand on this issue: Figure 5 takes four example HAQ values (0, 1, 2 and 3) and separately plots
the distribution of EQ-5D-3L health utility values for all the patients in the sample data that have
these HAQ scores.
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FIGURE 4 Distribution of EQ-5D-3L UK valuation in FORWARD (n= 100,398).
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FIGURE 5 Distribution of EQ-5D-3L scores at four different values of HAQ (FORWARD). (a) HAQ= 0; (b) HAQ= 1;
(c) HAQ= 2; and (d) HAQ= 3. Vertical dashed lines indicate the mean health utility of those four sample groups
(conditional distributions).
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Suppose we want to use our statistical model to predict EQ-5D-3L scores conditional on HAQ scores,
as might typically be the case for a cost-effectiveness model that had health states defined by these
HAQ scores. If α^, β^ and σ^2 denote the estimated parameters from the linear regression above, then we
can find our estimates of Equations 14 and 15 using:
EQ5Di^ = E½EQ5DijHAQi = α^ + β^HAQi, (16)
and σ^2, respectively. Equation 16 is our prediction, that is, our best guess of what the mean of the
conditional distribution (see Equation 14) is. These predictions must by definition be equal for every
individual with the same covariate(s): they yield the expected EQ-5D-3L value conditional on HAQ
value. Our prediction differs from the actual EQ-5D-3L value for any individual for two reasons. First,
Equations 14 and 16 will differ because of sampling error (assuming that the functional form is right).
α^ and β^ are estimated parameters associated with uncertainty because they are drawn from a finite
sample of patients. The degree of that uncertainty will reduce with larger samples. Second, for each
HAQ level, EQ-5D-3L differs from its mean by εi owing to variability between individuals in the
population. This variability is not reduced by increasing the sample size.
To this point, it would seem reasonable that we would want a mapping model to be able to predict
accurately, that is, we want the predictions from the model (the expected value conditional on covariates)
to be close to the sample means for patients with the same covariates, or at least to assess the reasons
why they are not close. What is not reasonable is to compare the distribution of the predicted values
with the distribution of the original data. Individual patients’ utility values exhibit marked variability, even
after conditioning on covariates, as illustrated in Figure 5. Predicted values from a mapping regression
model simply give the average values for a set of covariates, stripping out the variability.
Figure 6 illustrates this for the HAQ example. Figure 6a reproduces the original data from those
patients in the sample that had a HAQ of either 0, 1, 2 or 3. Figure 6b is the plot of the four predicted
values conditional on HAQ. These distributions are very different, as they should be. The fitted values
are conditional means, and therefore fit only four EQ-5D-3L values to each of the four HAQ values.
The raw data include patient-level variability that the predictions do not. Note, for example, that
no prediction yields a EQ-5D-3L value of 1 (full health) whereas in the original data there is a mass
of observations at 1, typical of the EQ-5D-3L. Even for the group of patients who indicated that they
have no functional disability (HAQ = 0), their mean EQ-5D-3L utility value is not 1. A utility value of 1
(full health) could be the mean for any set of patients with the same HAQ score only if every single
one of them had that EQ-5D-3L value of 1.
It would be valid, and indeed an important assessment of fit, to compare the predictions and the
means in the data (see the vertical dashed lines in Figure 5). In this example these predictions are
0.902, 0.664, 0.426 and 0.189 for HAQ values of 0, 1, 2 and 3, respectively. The sample means for
these same groups are 0.890, 0.692, 0.414 and –0.073, respectively: the point estimate of the mean
EQ-5D-3L for patients with a very high HAQ (extreme functional disability) is higher than the sample
average for that group by a substantial degree.
It is not valid to compare the distribution of the data to the distribution of the predictions. As discussed
in Predictions: mean versus distribution, it has often been claimed that mapping underestimates uncertainty,
meaning that the variance of the predictions is smaller than the variance of the sample data or that the
range of the predictions is smaller than the range of the data. Figure 6 shows that not only is the shape
of the distribution different between the predicted values and the sample data but the variance is indeed
also substantially lower in the former, as it should be. In fact, in this case, it is approximately half that
of the original data. But these two measures of ‘variance’ refer to two different concepts and are not
comparable. In fact, the variance of EQ-5D-3L in the sample is made up of two components: one relates
to the variability explained by the HAQ (i.e. the predictions) and the other relates to the variability of ε
(i.e. σ2). Thus, the variance of the original data is always higher than the variance of the predictions.
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Table 2 further illustrates this point with some examples from mappings that we have conducted.
The examples cover a range of models, PBMs and sample sizes. In all cases, the difference between
the variance of the sample data and the estimated variance from the model is negligible as expected.
Of course, the variance from the predicted values, which does not reflect the patient level variability,
is substantially lower.
In the case of mapping for CEA, good practice requires a reflection of the uncertainty around the
predicted values. The information with which to do this is contained in the variances (and covariances)
of the estimated regression coefficients, which are α and β in the linear regression HAQ example.
For non-linear models such as the ALDVMM, the covariance matrix of all the estimated parameters
is needed. This includes all the regression coefficients as well as all the variances of the error terms
because predictions for a non-linear model depend on all the model parameters. Repeated sampling
of the coefficients, drawing on the variance–covariance matrix, and using them in recalculating the
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FIGURE 6 Comparison of (a) the sample distribution and (b) the distribution of predictions for the FORWARD data with
HAQ values of 0, 1, 2 and 3.
DOI: 10.3310/hta24340 Health Technology Assessment 2020 Vol. 24 No. 34
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Hernández Alava et al. under the terms of a commissioning contract issued by the Secretary
of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be
included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for
commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha
House, University of Southampton Science Park, Southampton SO16 7NS, UK.
23
predictions generates the conditional distribution of mean EQ-5D-3L. This is a standard method used
to capture parameter uncertainty using probabilistic sensitivity analysis.79
Using mapping models to simulate data
The use of predicted values from mapping, with appropriate assessment of uncertainty, is clearly
important for economic evaluation. A standard cohort-based decision model would require exactly these
inputs. However, in some situations the cost-effectiveness analyst’s requirements will extend further.
Often there will be a need to not only estimate the mean health utility value for a health state defined
by the covariates in the mapping model but also impute actual data at the patient level. This would be
the case where an individual patient level simulation model is being used. Indeed, often this type of
model is used precisely because of the need to reflect patient variability to obtain an unbiased estimate
of cost-effectiveness.80 Alternatively, where a CEA is being undertaken alongside a clinical trial that has
not collected health utility information, mapping is used to impute missing data for each patient and, as
for all types of missing data, the analyst may not wish to simply impute the conditional mean value.
We described in Predictions: mean versus distribution, Predictions from mapping models, how the error
term, ε, for the linear regression allows the statistical model to reflect variability at the individual level.
The distribution of EQ-5D-3L conditional on HAQ will be normally distributed with mean equal to the
prediction (α^ + β^HAQi) and variance σ^
2. So we can simulate data from the regression outputs using
these assumptions about the error term to reflect the estimated degree of variability.
Figure 7 shows these predicted conditional distributions for our example HAQ values of 0, 1, 2 and 3 and
superimposes them on the corresponding conditional distributions from the original data (as in Figure 5).
TABLE 2 Variance of the sample data, estimated variance and variance of the predictions
Case study Data Linear
Mixture
ResponseALDVMM Beta
Rheumatoid arthritis: EQ-5D-3L51
Sample/estimated variance 0.070 0.068 0.066 0.065
Variance of the predictions 0.036 0.038 0.038
Ankylosing spondylitis: EQ-5D-3L53
Sample/estimated variance 0.098 0.088 0.097 0.091
Variance of the predictions 0.043 0.053 0.055
Heart disease: EQ-5D-5La
Sample/estimated variance 0.043 0.043 0.043
Variance of the predictions 0.026 0.026
Heart disease: SF-6Da
Sample/estimated variance 0.018 0.017 0.018
Variance of the predictions 0.012 0.012
Varicose veins: EQ-5D-3La
Sample/estimated varianceb 0.053 0.053 0.053
Variance of the predictionsb 0.010 0.009
Sample/estimated variancec 0.048 0.051 0.051
Variance of the predictionsc 0.013 0.012
a For study details, see Chapter 4.
b Pre-operation data.
c Post-operation data.
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FIGURE 7 Distributions of EQ-5D-3L by HAQ group: sample vs model. (a) HAQ= 0; (b) HAQ = 1; (c) HAQ = 2; and
(d) HAQ = 3. The dashed line represents the sample mean; the red line represents the mean prediction based on
the model.
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For our linear regression model we can see that the mean from the simulated values is close to the
sample means for each HAQ group, except those with a HAQ value of 3. The shape of that distribution
does not match very closely to the original data and it is not constrained to the feasible range of the
EQ-5D-3L. These features are important for assessing the credibility and suitability for potential uses of
a mapping model in subsequent cost-effectiveness analyses. Reporting of results in this way has helped
to demonstrate the performance of other model types previously.50,51,62
Model comparisons
The primary purpose of mapping models is to serve as an input to cost-effectiveness analyses.
Therefore, any model comparisons need to take into account the possible ways in which a mapping
model could be used in this context.
By far the most widely used criteria to select the appropriate model in the existing mapping literature
have been measures of goodness of fit of the model such as R2 /R2, and measures of predictive accuracy
such as mean error (ME), MAE and RMSE. There are several problems when using these measures as
model selection criteria in mapping. Mapping models are estimated using individual-level data and,
typically, relatively few covariates of potential relevance are available in the mapping data set and/or
have any realistic prospect of being used in the CEA. At the individual level there is substantial variation
and factors which are typically unobserved might determine the response variables. These unobserved
factors are often relatively large and, consequently, the data tend to be quite noisy, affecting measures of
goodness of fit (R2 /R2), which will tend to be relatively low compared with studies using more aggregated
data (see Predictions: mean versus distribution). Furthermore, the scale of the dependent variable, health
state utility, is small. Using the UK/England valuation sets, the length of the range intervals for the
EQ-5D-3L, EQ-5D-5L, SF-6D and HUI3 is 1.594, 1.285, 0.699 and 1.359, respectively (see Table 1).
The small range of values coupled with the relatively large contribution of unobserved factors results
in relatively insensitive measures of predictive accuracy (MAE and RMSE). Often, differences between
alternative mapping models will be detected only at the third or fourth decimal place of these measures.
Without recognising the constrained scale of health utility, it may be tempting to conclude that model
differences are slight and unimportant. However, even small differences can have serious consequences
for the CEA because the incremental benefit of an intervention appears in the denominator of the ICER.
Incremental benefits are typically quite small, so the ICER is very sensitive to very small differences
between mapping functions. Furthermore, MAE and RMSE are aggregate measures that might conceal
systematic patterns in the predictions. Systematic biases in the conditional means of the models may be a
sign of model misspecification.
Some studies report the ME. Where this is close to zero, as will be the case for a linear regression
estimated using OLS, this is used as support for the credibility of the mapping model despite the
concerns about its suitability raised in Chapter 2, Overview of different mapping approaches, Direct
methods. It is important to note that estimators such as OLS, which minimise the residual sum of
squares, essentially ensure that, as long as there is a constant term in the linear regression, the mean
of the predictions equals the mean of the dependent variable in the sample. Thus, the ME will be
effectively zero with slight departures owing to the numerical precision used in the calculation. In fact,
one could estimate a linear regression model without any covariates and find that just the inclusion of
a constant will yield a ME of approximately zero. This illustrates how this criterion for model selection
is not fit for the purpose of selecting a mapping model.
More recently, information criteria such as the Akaike information criterion (AIC) and the Bayesian
information criterion (BIC) have also been used. One complication of these information criteria, which
also applies to measures of goodness of fit such as such as R2 /R2, is that not all models that can be
used for mapping can be compared on this basis because models must have the same dependent
variable. In particular, direct and indirect approaches model different dependent variables and
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therefore their AIC and BIC cannot be compared directly. Models based on the beta distribution need
rescaling of the dependent variable to the range of the health state value set, invalidating comparisons
of AIC and BIC even with other models that use direct approaches.
Another important issue is that often these criteria select different models. MAE and RMSE are based
on different scoring functions that are computed at the individual level and then averaged to give
a summary measure of predictive accuracy. MAE and RMSE are similar in that all individual error
measures are positive, unlike ME, in which positive and negative errors can cancel each other out.
RMSE gives a higher weight to large errors owing to the squared terms and thus is sensitive to large
outliers. Some researchers prefer MAE whereas other researchers prefer RMSE because large errors
are seen as undesirable. In our case, this is not straightforward. Because mapping feeds into a cost-
effectiveness model, what is important will depend on the specific cost-effectiveness application. If the
feature that matters most for the specific CEA is not having any large errors, RMSE might be more
useful. However, in other cases MAE might be more appropriate to select the model. Therefore,
without knowledge of the specific CEA and the consequences of large versus small errors in utility
estimation, it is not possible to be prescriptive about which measure of predictive accuracy is better
in various scenarios. It is important, however, that as much information as possible is provided in an
accessible way so that the economic analysts using the results of the mapping can make a judgement
about its suitability for each specific application.
Both AIC and BIC may also lead to different models being selected. Both models are based on
penalised likelihoods but the penalty imposed for model complexity by BIC is higher than that for
AIC; thus, BIC will tend to choose models with less parameters than AIC. This issue always arises
when estimating mixture models with different numbers of components. Both AIC and BIC first
decrease and later increase with the number of components as the increasing number of parameters
starts to outweigh the benefits in terms of increased likelihood. The inflexion point tends to occur at a
lower number of components for BIC than for AIC owing to its higher penalty.
Hernández Alava et al.50 and, more recently, Fuller et al.54 have proposed some graphical methods
suited to the specific case of mapping to help with model selection as well as also providing vital
information for the economic analysts to select the right mapping model for their analysis and/or
design suitable for sensitivity analyses. These graphs have been shown to be of significant value when
deciding on the best mapping model in many applications (see Chapter 4 for several examples).
For many cost-effectiveness analyses it is only necessary that the mapping model is capable of
predicting the conditional means correctly without systematic biases that could affect the results of
the cost-effectiveness model. In other cases, patient-level simulation is required and the mapping
model needs to be able to reproduce the full conditional distribution of health utilities (see Predictions:
mean versus distribution). The graphical methods described in this section are based on attempting to
identify problems with the conditional means and the full conditional distribution, which could be a
sign of model misspecification.
The usual procedure of comparing the distribution of the predictions with the distribution of the data
is not appropriate and seemingly arises from confusion regarding what the term 'prediction' stands for
(see Predictions: mean versus distribution). The methods proposed here are based on (1) comparisons
of the predictions (conditional means) with means of the data grouped according to at least one of
the conditioning variables and (2) comparisons of the distribution of the data with the distribution of
the data that would be generated by the estimated model. These two points are important for model
selection because they highlight features that are important for a mapping model and directly relevant
to the economic analysts using the results of the mapping. These graphs reveal the presence (or
absence) of systematic problems in the conditional means (predictions) as well as problems with the
assumed underlying distribution that can cause both distortion of the conditional means and the full
conditional distribution.
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To illustrate the value of these graphs, a random sample of 3000 individuals from FORWARD (see
Chapter 4, Case study data set: FORWARD, for details of the survey) is used to estimate three different
models, mapping from the HAQ and pain to the EQ-5D-3L. The example mapping models are chosen to
demonstrate the usefulness of the graphs in identifying problems with the mapping models and their
use in practice (see Chapter 4 for practical applications in which these graphical methods are used with
a variety of mapping models). The three chosen models are (1) a linear regression, because this is one
of the most commonly used mapping models, (2) a two-part beta regression, because of its ability to
appropriately take into account the bounded nature of health utility data and the mass of observations
often present at full health (a restricted version of the beta mixture model in The beta mixture model,
with only one component), and (3) a three-component ALDVMM, which can, in addition, deal with
shapes not easily accommodated by a single distribution and the relatively large gap between full
health and the next feasible value. The beta mixture model (see The beta mixture model) could be used
in place of the ALDVMM without altering the conclusions; however, it has the added complication of
requiring a decision about whether or not to add mass points at the lowest utility value and the first
value below full health. To abstract from those complications, we used the ALDVMM instead. All
models use age, gender, HAQ and pain as conditioning variables.
Table 3 presents the usual measures of predictive accuracy and selection criteria for the three
estimated models. As expected, the ME of the linear regression is essentially zero by construction. The
linear regression shows the worst MAE and RMSE, but notice the small differences across the three
models. Owing to the rescaling of the dependent variable needed when using the two-part beta
regression, the only two models for which the information criteria can be compared are the linear
regression and the ALDVMM. Both AIC and BIC point towards selecting the three-component
ALDVMM.
It may be tempting to select the linear regression owing to its simplicity and the small differences in
MAE and RMSE. Plots of the predicted means versus data group means and distribution of the data
versus the distribution derived from the estimated model are very useful to aid understanding of
differences between models and the potential impact of those differences when translated into
economic evaluation. Figure 8 presents these plots for the three models. Figures 8a–c present the
graphs of the average group predictions versus the data means by intervals of HAQ. The linear
regression and the two-part beta regression have problems capturing the conditional means of the
EQ-5D-3L, especially at low values of EQ-5D-3L, where they systematically overpredict. If a health
technology were to increase the levels of HAQ from those low values, both mapping models would
tend to underestimate the benefit of the health technology. The two-part beta regression would
tend to do so to a lesser extent than the linear regression. It is also worth noting that, in this case, at
the highest levels of HAQ (extreme functional disability), the linear regression tends to overestimate
slightly the mean EQ-5D-3L, whereas the two-part beta regression captures that mean better. This
is expected because the two-part beta regression (estimated using the Stata command betamix,64
TABLE 3 Measures of predictive accuracy and model selection for a linear regression, a two-part beta regression and a
three-component ALDVMM
Measure Linear regression Two-part beta regression Three-component ALDVMM
ME –3.94e-17 0.01001 –0.00004
MAE 0.12896 0.12469 0.11861
RMSE 0.17084 0.16764 0.16495
AIC –2078.389 –3636.775a –3460.150
BIC –2048.357 –3570.705a –3315.997
a Note that the AIC and BIC of the two-part beta regression model are not comparable with the corresponding values
of the linear regression and ALDVMM owing to the rescaling of the health state values necessary when using
beta regressions.
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FIGURE 8 Plots of mean prediction vs. data group mean and cumulative percentage of actual data vs. model. (a) Linear
regression: means over HAQ DI groups; (b) two-part beta regression: means over HAQ DI groups; (c) three-component
ALDVMM: means over HAQ DI groups; (d) linear regression model; (e) two-part beta regression model; and (f) three-
component ALDVMM model. DI, disability index. (continued )
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FIGURE 8 Plots of mean prediction vs. data group mean and cumulative percentage of actual data vs. model. (a) Linear
regression: means over HAQ DI groups; (b) two-part beta regression: means over HAQ DI groups; (c) three-component
ALDVMM: means over HAQ DI groups; (d) linear regression model; (e) two-part beta regression model; and (f) three-
component ALDVMM model. DI, disability index.
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which allows for the gap) is designed to accommodate the large mass of observations at full health
and the gap and does this very well. The three-component ALDVMM captures the conditional means
fairly well across the different HAQ levels and does not exhibit any systematic patterns that could be
cause for concern. Figures 8d–f plot the cumulative percentage of EQ-5D-3L data versus the cumulative
percentage implied by the estimated models. Looking at these plots gives us an understanding of the
reasons behind the problems with the conditional means. There are several problems with the linear
regression. Although EQ-5D-3L data are bounded, there is nothing in the linear regression model that
restricts the distribution (and, therefore, its conditional mean) within the boundaries of EQ-5D-3L; this
may induce distortion in the distribution of the conditional means because in bounded distributions
the mean and the variance are related. Another problem is the presence of a large peak at full health.
Continuous distributions defined in the real space have very thin tails and find it difficult to generate
a mass of points at the end of the tail even after conditioning on the variables available for mapping.
As a result of these two issues, the estimated linear model generates points well above the full health
value of 1. In this case, the predictions (the means of the conditional distributions) are all below the
threshold value of 1, but it is not uncommon for even the conditional means to go above 1 when
predicting either within the sample or, even more commonly, out of sample when using the models in a
CEA. The two-part beta regression is specifically designed to deal with the mass of observations at full
health and the gap and fits that part of the distribution very well. What neither of these two models
can do is replicate the bimodality of the data, and their generated distribution completely misses those
observations at EQ-5D-3L levels < 0.5. Once enough flexibility is introduced, in this case through the
use of mixtures via the ALDVMM, the systematic overprediction of the conditional means at low levels
of HAQ disappears and the model seems to capture the conditional means much better overall, not
just at the bottom end. At the same time, the distribution implied by the estimated model is much
better aligned with the distribution of the data. Even if interest for a particular application lies only
in predicting the conditional means, model misspecification may distort those conditional means, as
shown in this example, and those problems cannot be appreciated by looking at only the standard
measures of prediction accuracy.
These plots also illustrate the theoretical issues highlighted in Chapter 2, Direct methods, and show,
on the one hand, the consequences of using a linear regression to model PBMs data in terms of
underpredictions/overpredictions of the conditional means and misspecification of the distribution
and, on the other hand, how allowing for the features of health utility data overcomes those problems.
The two-part beta regression is able to accommodate most of the health utility data features, so in
principle it is a good candidate; however, even a flexible distribution such as the beta distribution
cannot quite accommodate the features of the data. This is the reason why a finite-mixture version of
the two-part beta regression was developed during this project.
These plots are also very useful for analysts using the mapping models as a resource because they
clearly show the areas where the conditional means might not be accurate and where the full conditional
distribution is not fitting well. The information in the plots will guide the analysts in their decision about
selecting a mapping model if more than one is available and in identifying additional sensitivity analyses
that need to be carried out to assess the robustness of the results.
Validation of any statistical model should begin by looking at whether or not the model captures the
main features of the data within the sample. If there are obvious problems within the sample, such as
those described above for the linear model, these are only going to get worse when predicting out
of sample.
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Chapter 4 Case studies
This chapter presents a summary of the case studies used in this project. We include models thatare able to address all features of health utility data. We also include linear regressions in some
of the comparisons, given their popularity. Unidirectional case study comparisons concentrates on the
typical use of mapping from a disease-specific measure to a PBM. The findings from the case study
comparisons also apply to any model with a PBM measure as the target outcome measure, regardless
of the variables used to map from. Multidirectional mapping case study presents the findings for a case
study in which the aim was to get a single consistent model to map in two directions.
Unidirectional case study comparisons
We tested and compared the performance of different mapping methods in seven applied case studies
providing 15 data sets for comparison purposes. These case studies were selected to provide a broad
cross-section of disease areas, target PBMs and covariate types. Further details on these data sets and
how they may be accessed are available from the authors on request.
Case study data sets
Glasgow Outcome Scale
Data from the Victorian State Trauma Registry (VSTR) were used. The VSTR is a population-based
database that has collected information on all major trauma cases in the state of Victoria, Australia, since
2001.81 Patients are included if they meet any of the following criteria: injury severity score of > 12;
admission to critical care for more than 24 hours, with mechanical ventilation for at least part of that
time, as a result of injury; urgent surgery secondary to major trauma; or death due to injury. The study
population comprised consecutive adults (aged ≥ 16 years) enrolled in VSTR with significant traumatic
brain injury (TBI) (head-region abbreviated injury scale severity score of ≥ 3) and injured between
January 2008 and June 2013. The VSTR contains an extensive data set of demographic, physiological,
injury, investigation, and treatment and outcome variables. The study sample size was 3437.
Outcome in TBI effectiveness studies is conventionally assessed using the basic or extended Glasgow
Outcome Scale (GOS), measuring death and severity of disability using an ordinal scale. The basic scale
has five points, as shown in Table 4.
The extended scale expands levels 3, 4 and 5 of the basic scale, resulting in an eight-category scale
(Table 5).
TABLE 4 The basic GOS
Score Scale level Description
1 Death Severe injury or death without recovery of consciousness
2 Persistent vegetative state Severe damage with prolonged state of unresponsiveness and a lack of
higher mental functions
3 Severe disability Severe injury with permanent need for help with daily living
4 Moderate disability No need for assistance in everyday life; employment is possible but may
require special equipment
5 Low disability Light damage with minor neurological and psychological deficits
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Mappings to the EQ-5D-3L from both the basic and extended scales were performed. Full details of
the study are reported in Ward Fuller et al.54
Functional Assessment of Cancer Therapy-Breast
Data from three Phase III clinical studies of patients with locally recurrent or metastatic breast cancer
that measured both the EQ-5D-3L and Functional Assessment of Cancer Therapy-Breast (FACT-B)82
were pooled for this analysis. The three trials were as follows:
1. The Treatment Across multiple liNes wIth Avastin (TANIA) trial,83 which comprised 494 human
epidermal growth factor receptor 2 (HER2)-negative locally recurrent/metastatic breast cancer patients
whose disease had progressed on or after first-line bevacizumab combined with chemotherapy. They
were randomised to receive standard second-line chemotherapy either alone or in combination with
bevacizumab.
2. The MARIANNE study, which randomised 1095 patients with HER2-positive advanced breast cancer
to one of three treatment arms: control (trastuzumab plus taxane), trastuzumab emtansine plus
placebo or trastuzumab emtansine plus placebo plus pertuzumab.
3. The Batman study, which was an open-label, single-arm, multicentre UK study of the safety and
tolerability of bevacizumab when combined with taxane monotherapy as first-line therapy of
50 patients with triple-negative metastatic breast cancer.
The FACT-B is a self-reported instrument that measures health-related quality of life of breast cancer
patients.82 It comprises five subscales: physical well-being, social well-being, emotional well-being,
functional well-being and a breast-cancer-specific subscale. The subscales have seven items, with the
exception of emotional well-being, which has six items, and the breast-cancer-specific subscale, which
has nine. Items are rated from zero to four, with zero and four representing ‘not at all’ and ‘very much’,
respectively, and a total score is derived. Items can be positive or negative, for example ‘I have lack of
energy’ or ‘I feel close to my friends’. Higher scores for negatively worded items correspond to better
health. The total FACT-B score ranges from zero to 123, and is calculated by adding the scores from
each of these subscales after accounting for negative or positive wording. Lower scores indicate better
health in this scoring.
Full details are reported in Gray et al.84
Sydney Asthma Quality Of Life Questionnaire
We used data from the Multi-Instrument Comparison (MIC) project data set, which collected data from
respondents in six countries: Australia, Canada, Germany, Norway, the UK and the USA.85 In total, 8817
individuals completed 12 instruments relating to their health or well-being. Data were collected from a
representative healthy cohort and from patients in eight clinical areas. The study was designed to allow
TABLE 5 The extended GOS (GOSE)
Score Scale level
1 Death
2 Vegetative state
3 Lower severe disability
4 Upper severe disability
5 Lower moderate disability
6 Upper moderate disability
7 Lower good recovery
8 Upper good recovery
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comparisons between health and well-being instruments. Patients who self-reported specific health
conditions were asked to complete disease-specific outcome measures as well as numerous other
generic outcome measures for well-being and health utility. In total, 856 respondents self-reported
asthma and completed the Sydney Asthma Quality of Life Questionnaire (AQLQ-S). Data were available
for respondents’ age and sex as well as their EQ-5D-5L and HUI3 values. After removing observations
with missing values in any of the required variables, the final sample for analysis was 852.
Gray et al.37 report as follows:
The AQLQ-S was designed as a measure of quality of life for adult patients with asthma. The questionnaire
contains 20 questions within four domains (symptoms, activity limitation, emotional function and
environmental stimuli). Each of the questions allows a response on a 0–4 scale, with zero representing no
problems at all. The scores for each question are averaged to produce an overall AQLQ-S score between
zero and four. Although there are many different versions of the AQLQ, the AQLQ-S is recommended by
the European Medicines Agency (EMA)86 and has been validated.87
Reproduced with permission from Gray et al.37 © 2018 International Society for
Pharmacoeconomics and Outcomes Research (ISPOR). Elsevier Inc. This is an Open Access article
distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license,
which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided
the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
MacNew Heart Disease Health-related Quality of Life questionnaire
We again used data from the MIC study.85 The MIC data set contains variables on demographic
variables, health and well-being, disease-specific health measures and health state utility measures.
Disease-specific questionnaires were given to patients who self-reported the relevant diseases. In total,
943 respondents self-reported having heart disease and completed the MacNew Heart Disease Health-
related Quality of Life (MacNew) questionnaire. Data were available on respondents’ age and sex as
well as their EQ-5D-5L and SF-6D values in all cases, leaving a final sample of 943 observations.
The MacNew questionnaire was developed to measure quality of life in heart disease patients. The
questionnaire contains 27 questions and generates an instrument that aims to quantify the effects
of heart disease and treatment of heart disease on physical and emotional health as well as social
function. Each of the questions allows a response on a scale of one to seven, with one representing the
most severe problems and seven representing no problems at all. The scores for each question are
averaged to produce an overall MacNew score between one and seven.
European Organisation for Research and Treatment of Cancer quality of life
questionnaire
We used data from the Trastuzumab emtansine versus treatment of physician’s choice for pretreated
HER2-positive advanced breast cancer (TH3RESA) study. TH3RESA was an open-label, phase-III trial
that randomised patients from 14 September 2011 to 19 November 2012. A total of 602 patients
recruited from medical centres in 22 countries across Europe, North America, South America and
Asia-Pacific took part. Eligible adult patients had HER2-positive, unresectable, locally advanced or
recurrent breast cancer or metastatic breast cancer and had received two or more HER2-directed
regimens in the advanced setting, including trastuzumab and lapatinib, and previous taxane therapy in any
setting, and were randomly assigned (in a 2 : 1 ratio) to trastuzumab emtansine (3.6 mg/kg intravenously
every 21 days) or physician’s choice.88 Patients with non-measurable or measurable disease according to
Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 were enrolled. Patients completed the
European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-
Core 30 (QLQ-C30)89 version 3c90 at the same time as they completed the EQ-5D-3L questionnaire, from
day one of each treatment cycle until study treatment discontinuation or investigator-assessed disease
progression. The trial included the EQ-5D-3L and we use the UK value sets.5 The data contains multiple
observations from each individual. We report robust standard errors to reflect this.
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The EORTC QLQ-C30 is an integrated system for assessing the health-related quality of life of cancer
patients participating in international clinical trials. The QLQ-C30 comprises 30 questions and is a
commonly used outcome in clinical trials as well as in other non-trial clinical studies. At the time
of writing, the instrument had been used in > 3000 studies.91 The QLQ-C30 is composed of both
multi-item scales and single-item measures, which include a global health status/quality-of-life scale, five
functional scales (physical, role, emotional, cognitive and social function), three symptom scales (fatigue,
nausea and vomiting, and pain), and six single items (dyspnoea, insomnia, appetite, constipation, diarrhoea
and financial difficulties). All are expressed on a scale of 0–100, with higher scores representing higher
levels of functioning, higher quality of life or higher levels of symptoms.
Oxford Knee Score
We use data from the 2009–14 PROMs data set with information on > 170,000 patients. These
data hold information on a number of disease-specific PROMs and PBMs. The data includes patients
suffering from knee problems and contains their Oxford Knee Score (OKS) score, as well as their
EQ-5D-3L measure, both before and 6 months after knee replacement surgery. The data also contain
information on sex and age group (40–49, 50–59, 60–69, 70–79, 80–89 and 90–120 years of age).
The OKS was developed in 199892 shortly after the Oxford Hip Score.93 Both are questionnaires that
record patient-reported outcomes. The OKS was developed to be used in randomised controlled trials
to record patient outcomes before and after surgery to help assess the success of surgery without the
bias of surgeon-reported outcomes. The OKS concentrates heavily on instruments related specifically
to the knee to prevent comorbidities from biasing results. Questions focus on pain, mobility and self-
care. (See Dawson et al.92 for a more detailed description of the questionnaire and its development.) It
consists of 12 questions scored between zero and four, resulting in a total score between zero and 48,
with 48 being the best possible response and zero representing the most severe response to every
question.
Aberdeen Varicose Vein Questionnaire
We used data from the PROMs data set from 2009 to 2014, which holds information on > 170,000
patients. These data contain information on a wide range of outcome measures, both disease-specific
and preference-based general health measures. The data includes patients suffering from varicose veins
and records their Aberdeen Varicose Vein Severity (AVVS) score as well as their EQ-5D-3L measure;
PROMs also provides information for the patients before and 3 months after they have surgery. We
performed separate analyses on the pre- and post-surgery data. Data are available for 25,266 patients
with valid AVVS scores in at least one time period, before or after surgery. The data also contain
information on sex and age group (40–49, 50–59, 60–69, 70–79, 80–89 and 90–120 years of age).
After observations with missing values have been removed, there are 13,337 and 8610 patients with
information in all required fields, before and after surgery, respectively.
The AVVS score was developed in 1993 to produce a reliable outcome measure for patients suffering
from varicose veins.94 The questionnaire, developed by Garratt et al.,94 includes a range of questions
referring to the patient’s experiences relating to their varicose veins during the most recent 2 weeks,
including questions on pain, use of medication, swelling, itching and rash. Answers to these questions
are then added together and used to create a score between 0 and 100, where 0 is no symptoms and
100 corresponds to the most severe answer to each of the questions. The AVVS has been validated in
previous studies.95
Table 6 provides an overview of the key characteristics of the mapping case studies. We did not
consider the same model types in all case studies. These studies were used to develop the evidence
base, with each study conducted sequentially and selecting or developing model types for testing based
on the findings of previous studies.
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Results
Results are summarised in Table 7.
Glasgow Outcome Scale
The GOS study compared different specifications of the ALDVMM in terms of the number of latent
classes and the covariates. The first set of models presented used a small number of covariates: basic
GOS category and age. These appeared both as explanatory variables within each component and also
explained the probability of component membership. From these models, the three-class model was
selected as the optimal model because the addition of a fourth class improved model fit only marginally
and at the expense of increased model complexity. The three-class model had lower BIC but other fit
statistics favoured the four-class model.
The more detailed model showed a similar pattern in the results. Additional covariates were included in
these models: sex, comorbidity and extra-cranial injury. The three-class model was again the preferred
version. This version had the lowest AIC, MAE and RMSE.
In both cases, there was evidence of very good fit across the EQ-5D-3L severity range. This was true
for within-sample fit and in an out-of-sample comparison of scores provided by patients 24 months
post injury. There was a small degree of underprediction of EQ-5D-3L for those in good health.
Using the extended GOS as the explanatory variable in both the basic (including only age) and detailed
model (additional covariates of gender, comorbidity and extra-cranial injury) yielded similar results.
However, in both cases the four-class models were deemed optimal. These performed best in terms
of AIC, MAE and RMSE inter alia. Within-sample and out-of-sample prediction of EQ-5D-3L at 12
and 24 months post injury also showed excellent agreement between observed and predicted values.
However, there was again minor underprediction of EQ-5D-3L at 6 months for those patients with
little or no functional disability.
Functional Assessment of Cancer Therapy-Breast
The FACT-B study compared ALDVMM and response mapping models. ALDVMM models beyond four
classes had problems with convergence and could not be estimated. The response mapping models were
estimated using seemingly unrelated regression ordered probits. Only FACT B and age were used as
explanatory variables. There were only very small numbers of males in the data set.
TABLE 6 Summary details of mapping case studies
Disease area n Target PBM Primary covariates Methods
Brain injury 3437 EQ-5D-3L GOS ALDVMM
Breast cancer 11,958 EQ-5D-3L FACT-B (summary score
and individual items)
ALDVMM, response mapping
Asthma 856 EQ-5D-5L, HUI3 AQLQ-S Beta mixture, ALDVMM,
linear regressiona
Heart disease 943 EQ-5D-5L, SF-6D MacNew questionnaire Beta mixture, ALDVMM,
response mapping
Breast cancer 3765 EQ-5D-3L EORTC QLQ-C30 ALDVMM, linear regression,
response mapping
Knee surgery 136,327 EQ-5D-3L OKS Beta mixture, ALDVMM,
response mapping
Varicose veins 13,337 pre surgery;
8610 post surgery
EQ-5D-3L Aberdeen Varicose Vein
Questionnaire
Beta mixture, ALDVMM
a Response mapping was not feasible owing to an insufficient number of observations in each response category.
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For the models that used the FACT-B total score, the preferred model was the three-class ALDVMM.
Although the four-class model had lower AIC and BIC, other measures of fit favoured the three-class
variant, including the assessment of fit over the range of disease severity measured by FACT-B. The
three-class model demonstrated close fit to the data at all levels except the most severe disease, where
data were scant. The difference between the observed and predicted values at this level of disease
severity was within 95% CIs. Simulated data from both the three- and four-class models fit the observed
data very closely. Performance of the ALDVMM models was substantially better than response mapping.
This applies to both the measures of summary fit and assessment of model performance at different
parts of the distribution. The response mapping was particularly poor at the severe disease level.
Using the subscales for FACT-B as covariates improved model performance for all types, as expected.
Again, the three-class ADLVMM was preferred, although performance of the four-class model had
lower MAE and RMSE. Interestingly, although the performance of the response mapping approach
TABLE 7 Summary of model comparisons performed in case studies
Study PBM
Optimal number
of classes,
n (n tested)
Covariates
for class
probabilities Model comparisons ranking
ALDVMM
Beta
mix
Disease
severity Age 1 2 3
GOS basic, simple
model
EQ-5D-3L 3 (4) Yes Yes ALDVMM
GOS basic, detailed
model
EQ-5D-3L 3 (4) Yes Yes ALDVMM
GOS extended, basic
model
EQ-5D-3L 4 (4) Yes Yes ALDVMM
GOS extended,
detailed model
EQ-5D-3L 4 (4) Yes Yes ALDVMM
FACT-B, summary
score
EQ-5D-3L 3 (4) Yes Yes ALDVMM Response
mapping
FACT-B components EQ-5D-3L 3 (4) Yes Yes ALDVMM Response
mapping
AQLQ-S EQ-5D-5L 3 (4) 3 (4) Yes Yes Beta
mixture
ALDVMM Linear
model
AQLQ-S HUI3 4 (4) 4 (4) Yes Yes Beta
mixture
ALDVMM Linear
model
MacNew EQ-5D-5L 3 (4) 3 (4) Yes Yes ALDVMM Beta
mixture
MacNew SF-6D 4 (5) 4 (5) Yes Yes ALDVMM Beta
mixture
EORTC QLQ-c30 EQ-5D-3L 4 (5) Yes No ALDVMM Linear
model
Response
mapping
OKS (pre operation) EQ-5D-3L 4 (4) 3 (4) ALDVMM Beta
mixture
OKS (post operation) EQ-5D-3L 3 (4) 3 (4) ALDVMM Beta
mixture
AVVS (pre operation) EQ-5D-3L 3 (3) 3 (3) Yes Yes ALDVMM Beta
mixture
AVVS (post operation) EQ-5D-3L 4 (4) 4 (4) Yes Yes ALDVMM Beta
mixture
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improved, in many aspects this still did not yield a model that performed as well as the ALDVMM
models based on total FACT-B score. In particular, the ALDVMM performed better than the response
mapping approach in the middle section of the disease severity distribution.
Sydney Asthma Quality of Life Questionnaire
The AQLQ-S study37 compared a number of variants of the ALDVMM and beta mixture models
predicting both EQ-5D-5L and HUI3. Because much of the testing of models had previously focused on
the three-level EQ-5D, these model variants allowed us to see whether different features of the models
were still required when modelling utility instruments that did not have such pronounced features as
the EQ-5D-3L. For example, both instruments have a gap between full health and the next feasible
health state (these next feasible health states are 0.951 in the EQ-5D-5L and 0.97258 in the HUI3).
The gap created by the ‘truncation point’ in the HUI3 is substantially smaller than that in the EQ-5D-3L
and, therefore, may not be a requirement for inclusion in models. We tested both types of mixture
models with and without the inclusion of this truncation point and with and without the inclusion of a
probability mass at this truncation point (beta mixture models).
Response mapping could not be conducted because the data lacked observations in each of the response
categories of the EQ-5D-5L and HUI3 instruments. Linear regression was also used to provide further
comparisons with this method.We included the AQLQ-S summary score, age, age squared and sex as
covariates in all parts of the models. We also ran models that included the individual dimension scores of
the AQLQ-S rather than the total score but found that results were not significantly improved.
When modelling the EQ-5D-5L, it was found that models that included the gap between full health
and the next feasible value outperformed those that did not. Beta mixture models required the formal
addition of a probability mass at full health to perform sufficiently well. This is an in-built feature of the
ALDVMM, which does not require any adaptation to achieve this. Models without a probability mass at
the truncation point did not perform better than those that omitted it. For these reasons, the optimal
beta-based model has three components and a probability mass at full health but not at the truncation
point. The optimal ALDVMM also had three classes. The four-component model offers improvements in
RMSE, MAE and ME but has a higher BIC. Model fit over different disease severities was very similar
between the three- and four-class models.
For the HUI3 model, we found that beta mixture models had to formally model the gap in utility values
and incorporate a probability mass at full health. The best-performing model also included a probability
mass at the truncation point and had four components, although the three-component model had a lower
BIC. The ALDVMM’s performance varied by the number of components but also the inclusion of different
covariates.We found that model fit was improved by the inclusion of age in the model probabilities.
Linear models performed worse for both explanatory variables in almost all relevant areas of
model selection.
MacNew Heart Disease Health-related Quality of Life questionnaire
Models were compared using both EQ-5D-5L and SF-6D score as the dependent variables.
In the case of the EQ-5D-5L, for the ALDVMM the performance of three- and four-class models was
very similar. The BIC favoured the three-class model and, although MAE and RMSE were superior for
the four-class variant, there was very similar graphical fit. Therefore, we preferred the three-class
model. Beta mixture models used the same set of covariates, including MacNew score and age, in the
component probabilities. Because there were only 10 observations at the truncation point, the best-
fitting beta mixture model included a mass point only at full health. Beta models produced marginally
improved summary fit statistics compared with the ALDVMM models with the same numbers of
components. However, it needs to be recognised that a three-component beta mixture model has more
DOI: 10.3310/hta24340 Health Technology Assessment 2020 Vol. 24 No. 34
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Hernández Alava et al. under the terms of a commissioning contract issued by the Secretary
of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be
included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for
commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha
House, University of Southampton Science Park, Southampton SO16 7NS, UK.
39
parameters in general than a three-component ALDVMM (31 vs. 26, respectively). Based on parsimony,
we recommend the ALDVMM three-class model.
In the case of the SF-6D, we tested ALDVMM models up to five classes but found that the four-class
model was preferred. This offered some improvement in fit over the three-class model. The specification
of the beta mixture models was determined in part by the distribution of SF-6D utility values in this
sample. There were only three observations at full health and, therefore, models with a probability mass
at this point were not feasible. Similarly, there was only one observation at the lower limit and small
numbers at the truncation point. Therefore, the beta mixture models did not include mass points at any
of these three options. The ALDVMM models performed slightly better than the beta mixtures with
equivalent numbers of components. The beta models also exhibited poor fit for those in the most severe
MacNew-defined health states. This issue was absent from the ALDVMM models.
European Organisation for Research and Treatment of Cancer Quality of Life
Questionnaire-Core 30
The ALDVMM models with up to five components were estimated, using the component scores of
QLQ-C30 as explanatory variables. We found that the likelihoods for the five-component models were
unreliable owing to very small variances. The optimal model has four components and included both
disease-specific variables and age within the components. Only the global health status component of
the QLQ-C30 was included in the class probabilities.
This model was preferred over both linear regression and response mapping (implemented using
generalised ordered probit models).
Oxford Knee Score
Separate analyses were conducted of pre- and post-surgery data.
Response mapping using seemingly unrelated ordered probit models had clear problems fitting the
data. The model focuses on fitting the parts of the distribution for which there are a larger number of
observations at the expense of other parts of the distribution; in the pre-operation sample, predictions
are poor at both the upper and the lower end of the distribution, whereas the post-operation sample is
predicted relatively well at the upper end of the distribution but even more poorly at the lower end.
However, this was not reflected in the summary fit statistics, which were equal to the direct, mixture-
model-based approaches.
We found that the ALDVMMs, which included a gap between full health and the next feasible health
state, consistently outperformed the equivalent model, which does not allow for this gap. The four-
component model was the preferred variant. This was based on both the AIC and the BIC and also on
the plot of the conditional distribution, which showed improved fit at the lower end of the distribution
(EQ-5D-3L value < 0.25).
Like the ALDVMMs, the beta mixture models were consistently better fitting when a gap was included in
the model between full health and the next feasible health state. The best-fitting models were those that
included probability masses at full health, at the next feasible heath state and at the worst possible
health state. The addition of a fourth component made very little difference to the model; thus, we
recommend the use of the three-component model.
There was little to distinguish between the performance of the ALDVMM and beta mixture models for
equivalent numbers of components when compared using plots of mean EQ-5D-3L by mean OKS or
the cumulative distribution plots. The beta mixtures entail more parameters than the ALDVMM and
are more arbitrarily adjusted to suit the data. Therefore, the ALDVMM model is marginally preferable.
The results for the post-operative data were very similar. Here, the poorer performance of the response
mapping approach was also evident in the summary fit statistics. The ALDVMM three-component variant
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was preferred to the four-class model. The summary fit measures are very similar between the ALDVMM
and beta mixture models and are therefore not conclusive in selecting a preferred model. The plots of the
predictions also revealed no significant differences. The four-component model adds a component at
around 0.6, in contrast with the three-component model, allowing a subtle improvement in model fit
around this area of the EQ-5D-3L distribution. However, this improvement in fit is minor and does not
warrant the addition of the extra component.
Beta mixture models that include a gap performed better than those that do not in the post-operative
sample, both in terms of summary fit and from visual inspection of the predicted values and the
cumulative distribution plot. We also found that the better-fitting models are those that do not include
probability masses at the point adjacent to full health or the worst possible health state.
Aberdeen Varicose Vein Questionnaire
The AVVS score was used as the dependent variable in two types of mixture model analyses:
ALDVMM and beta-based mixture models.
For the pre-operation data, we found that the beta-based mixture models performed better with three
components than with two. Models required the inclusion of a probability mass at full health but results
were equivocal between models, with no further probability masses versus those with truncation included
at the gap after full health and a probability mass.Whereas AIC/BIC favoured the former, other measures
of fit, including visual inspection of the mean EQ-5D-3L by AVVS, favoured the latter. The analyses using
the ALDVMM approach also showed that three-component specifications outperformed those with two
components, irrespective of other aspects of the specification. Further comparisons were made between
ALDVMMs that excluded the modelling of the truncation point below full health and the inclusion of
squared AVVS terms both in the component probabilities and as explanatory variables within components.
Models with truncation performed universally better than those without truncation.We also found that
excluding the squared terms from the component probabilities produced the best-performing models in
terms of mean fit, excluding AIC and BIC. However, visual inspection of the plots of mean EQ-5D-3L by
AVVS showed that the exclusion of the squared term vastly improved model performance at the lower end
of the AVVS, the worst degree of disease severity. Identification of the best model was challenging in part
owing to limited data at high disease severity levels. This specification of the ALDVMM had lower MAE
than the beta mixture model, excluding RMSE. There is very little to distinguish between the ALDVMM
and the beta mixture models, although the ALDVMMs are simpler and more generalisable because they do
not need the introduction of ad hoc probability masses at the boundaries.
A very similar pattern of results was found when modelling the post-operative data. Here, four-
component models were required to be tested and found to be better performing, for both the beta
mixture and the ALDVMM approaches. It was unclear which model type to favour because the results
showed that summary fit measures conflicted with each other and there was very little difference
across the distribution of AVVS.
Findings
Seven disease areas provided 15 case studies in which mapping methods were applied. The case studies
included the EQ-5D-3L (n = 11), EQ-5D-5L (n = 2), SF-6D (n = 1) and HUI3 (n = 1) as dependent variables.
Adding to what is a substantial existing literature, and in line with expectations based on the conflict
between the form of utility data and the assumptions inherent in the statistical model, linear
regression is shown to perform poorly.
We found that, in all case studies, the more flexible methods for direct utility mapping, which draw on
different variants of mixture models with appropriately specified underlying distributions, perform very
well. However, the precise form of those models matters.
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A minimum of three components are required in mixture models when modelling the EQ-5D-3L,
EQ-5D-5L, SF-6D or HUI3. This is in line with our previous experience. In some cases, we found that
fitting more than four components was not feasible given the constraints of the data sets available.
Nevertheless, good model performance was achieved in all cases.
Typically, the shape of the utility distributions tends to change by case study as a factor of the utility
instrument being modelled, the nature of the disease area and the severity of the patient sample. To
address this requires the inclusion of covariates that represent disease severity as predictors of the
component membership probabilities. The optimal models in all case studies included disease severity
both within components and as predictors of component membership.
In most applications, age and gender tend to modify the conditional mean of the classes but are less
important in determining the probabilities of component membership.
Spurious clusters are not easy to identify in the left tail of the distribution of the EQ-5D-3L. Often,
there is a small number of individuals in very poor health, which might need a separate component
distribution. Judgement needs to be exercised in these circumstances as this small component
distribution might represent a spurious cluster or a separate component for a small number of
individuals. In this case, a component with a small number of individuals is perfectly fine.
The findings clearly demonstrate that there are multiple features of data from utility instruments that
need to be reflected in the design and application of appropriate models. It is not simply the case that
models need to account for the mass of observations at 1, and the limited nature of the dependent
variable. The asthma example in particular shows that, even for the case of the EQ-5D-5L and HUI3,
for which the gap is much less pronounced than for the EQ-5D-3L, models that reflect these features
perform better than those that do not. We tested this with both different specifications of the beta
mixture models and the ALDVMMs (which without the gap at this point become mixtures of tobit-
type models).
Finally, simply applying the ALDVMM or beta mixture methods does not in itself provide any protection
against misuse nor ensure better fit. These are challenging models to apply and they need to be combined
with detailed consideration of the number of components, the inclusion of different truncation points,
covariates, their form and whether they appear within the components or in the component probabilities.
Good practice needs to be followed in estimation to ensure that the models have genuinely converged.
This is a skilled job and, without appropriate application, results can be misleading. Guidance and
examples of application of these methods can be found elsewhere.64,67 The model comparisons we
conducted are examinations not only of the performance of broad model types against each other but
also of different specifications of these models.
Multidirectional mapping case study
We tested the response mapping model presented in Chapter 3, Indirect methods: systems of ordinal
regressions using copulas, in a single case study.
Case study data set: FORWARD
FORWARD, the National Databank for Rheumatic Diseases, is the largest patient-reported research data
bank for rheumatic disorders in the USA. It is a register of patients with rheumatoid disease, primarily
recruited by referral from US and Canadian rheumatologists. Information supplied by participants is
validated by direct reference to records held by hospitals and physicians (a minority of cases come by
self-referral, with medical details obtained by FORWARD in the same way). Full details of the recruitment
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process are given by Wolfe and Michaud.78 Data are collected by various means, primarily postal and
web-based questionnaires completed directly by patients. Data collection began in 1998 and continues to
the present, in two waves per annum administered in January and July. In 2011, there was a switch from
the EQ-5D-3L to the EQ-5D-5L and both versions were collected simultaneously during the January 2011
wave. The questionnaire includes many general as well as rheumatoid-disease-specific questions. The HAQ
disability index is based on patient self-reporting of the degree of difficulty experienced over the previous
week in eight categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip and common
daily activities. It is widely used by clinicians to measure health outcomes. It is scored in increments of
0.125 between zero and three (although it is standard to consider it fully continuous), with higher scores
representing greater degrees of functional disability. The HAQ instrument also includes, separately, a
patient self-report of pain scored on a visual analogue scale (0–10).70 To calculate the expected utilities,
the UK and English value sets are used for the EQ-5D-3L and EQ-5D-5L, respectively.5,6 The study sample
size for this case study using only the January 2011 wave was 5192.
Results
The case study used seven covariates: age, gender, the HAQ disability index, the pain scale, and the
squares and product of the HAQ and pain scales (i.e. HAQ squared, pain squared and the product of
HAQ and pain). A number of different model specifications allowing different number of covariates,
mixtures and different copulas for each of the EQ-5D dimensions were tested. The copulas used included
Gaussian, Frank, Clayton, Gumbel and Joe copulas (see Chapter 3, Indirect methods: systems of ordinal
regressions using copulas) as well as a model of independent EQ-5D dimensions as is conventional in
response mapping models.
The selected optimal model according to both AIC and BIC was a joint model with a common mixture
for the errors across all 10 equations and different copulas for different dimensions of EQ-5D:
Gaussian copulas for mobility and usual activities, Frank copulas for self-care and anxiety/depression
and a Gumbel copula for pain/discomfort.
We found that a flexible specification revealed significant differences between individuals’ responses to the
EQ-5D-3L and EQ-5D-5L. The differences were particularly large for the mobility and pain dimensions of
the EQ-5D, which are the most important dimensions of the EQ-5D for patients with rheumatoid disease.
In terms of the utility values, the EQ-5D-5L utility values tended to be systematically higher than the utility
values of the EQ-5D-3L so that the distribution function for the EQ-5D-3L was always to the left of the
distribution function for the EQ-5D-5L.
To assess the likely impact of these differences together with those introduced by the valuations in an
economic evaluation, we used for this case study a trial of combination drug therapies for RA.96 The
original economic evaluation was carried out using the EQ-5D-3L. Using the model to map EQ-5D-3L
responses to the EQ-5D-5L, we repeated the economic evaluation in terms of the EQ-5D-5L and found
in this case study that the magnitude of the ICERs increased when using the EQ-5D-5L by > 100% in
some cases. This result was due to (1) the significant differences to the responses to the mobility and
pain dimensions between the two versions of the EQ-5D and (2) the different structures of the
valuation systems.
Making the assumption of independence across the EQ-5D dimensions, as is usual in response mapping,
or using a restricted set of covariates could also cause a large shift in the ICER.
Full details of the results are reported in Hernández-Alava and Pudney.70
To check the generalisability of the results, we also estimated different specifications of the same
statistical model in another data set.97 A range of case studies was used to assess the impact of the
differences between the EQ-5D-3L and EQ-5D-5L on additional cost-effectiveness studies in different
disease areas in the UK.
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Findings
This case study highlights, yet again, the importance of taking into account how the model is going to
be used to either select from the pool of already available models or develop an appropriate model for
the task.
This case study set out to establish the differences between the two versions of the EQ-5D at two
levels, the responses to the classification system and the additional differences introduced by the
different valuations. Any direct mapping approach will be able to provide only the overall joint effect.
Thus, a response mapping approach is needed in this case, but it needs to be flexible enough so that
we minimise the risk of imposing restrictions that will bias our results.
A substantial part of the increase in the ICER of the RA case study was due to the different structures
of the valuations, suggesting that a similar overall result could be expected in other disease areas.
Additional case studies found a similar result: moving from the EQ-5D-3L to EQ-5D-5L decreased
the incremental QALYs, increasing the ICER in the majority of cases. The additional case studies
also revealed that, for technologies with significant mortality gains, the ICER could change in either
direction when moving from the EQ-5D-3L to EQ-5D-5L because improved survival is given a greater
value under the EQ-5D-5L owing to the systematic increase in utility values relative to the EQ-5D-3L.
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Chapter 5 Additional methodological
issues around mapping
The validity of multi-instrument data sets used for mapping: the
monotonicity concept
There are several settings in which mapping can be used. The types of statistical models that should be
applied are the same, because they are driven by the distributional shape of the dependent variable, but,
conceptually, they deal with different issues. The most common type of case involves mapping from a
disease-specific measure to a PBM, as in the case studies covered in Chapter 4, Unidirectional case study
comparisons. A second type of case maps from one PBM to another: the case study presented in Chapter 4,
Multidirectional mapping case study, is an example of this, although mappings between PBMs do not
necessarily have to be multidirectional. A third type of case, which is not usually thought of as mapping
but is statistically equivalent, involves modelling a PBM conditional on covariates that are not necessarily
clinical measures, for example to explore the relationship between the EQ-5D-3L and BMI controlling for
other important factors.98
Mapping is likely to work well only if the set of conditioning variables is able to identify a similar concept
to that captured by the PBM. In the third type of case described above, this may be achieved by using
a large number of relevant conditioning variables. However, this is often not possible in the first two
types of case, in which few covariates are typically available. In the first type of case, mapping from a
disease-specific measure to a PBM, it is important that all relevant variables are used in the mapping.
Hernández Alava et al.50 showed that the inclusion of pain (which is part of the HAQ questionnaire but
not part of the HAQ disability index summary score) greatly improves models mapping from the HAQ to
EQ-5D-3L because pain is an important dimension of the PBM.
In the second type of case, mapping between two PBMs, mapping without additional covariates will
work well only if the two outcome measures are closely related in the sense that they are designed to
measure the same (or very similar) theoretical concepts. However, this implies that the questionnaire
generating the multi-instrument (MI) data set presents the respondent with two sets of very similar
questions. This near repetition in an interview may influence response behaviour, leading to systematic
differences between the responses that would be given in a MI reference sample and in a conventional
single-instrument survey. Such response distortion could lead to bias in the mapping procedure (see
Schuman and Presser99 for a survey of the influence of questionnaire context).
Given these concerns, an important first step is to provide empirical evidence on the extent of conflicts
between the orderings of health states provided by the two measures. To do that, we introduced the
concept of ‘monotonicity’ and corresponding sample estimates of monotonicity rates. This section
outlines the approach and gives a flavour of the results for the FORWARD data set, described in
Chapter 4, Case study data set: FORWARD, which implements two PBM measures: the EQ-5D-3L and
EQ-5D-5L.
Consider the problem of mapping from one health description, X, to an alternative description, Y. X and Y
are both vectors, with each element of X or Y describing health in a particular dimension. For example,
in our application of mapping the EQ-5D-3L to EQ-5D-5L, X and Y are both five-dimensional vectors,
with the dimensions corresponding to mobility, self-care, usual activities, pain, and anxiety/depression.
The MI data set contains observed responses for both X (EQ-5D-3L) and Y (EQ-5D-5L) for a sample of
n individuals.
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We can say that instruments X and Y are perfectly coherent (or technically monotonic) if, when instrument
X orders two health states unambiguously in a particular way, the instrument Y always orders them in the
same way. For example, if the health of an individual improves between two different time points when
the individual completes the EQ-5D-3L but declines according to their EQ-5D-5L responses, then there
is a problem of non-monotonicity between the responses of the individual. Because CEA studies use
utility values to convert health outcomes into QALYs, if the measurement instruments do not display
monotonicity it is impossible to construct equivalent, theoretically valid, utility scales for the two
instruments. There would then be cases in which the two measures would generate irreconcilable QALY
estimates, giving problems for decision-making based on evidence from the two different measurement
instruments. Modest degrees of non-monotonicity should always be expected in applied work because
there is likely to be some response ‘noise’ in the data. However, extensive inconsistencies between health
state orderings would be a cause for concern, particularly if the inconsistency is concentrated in regions of
the distribution of health states that are critical for the outcome of major CEAs.
Ideally, monotonicity would be assessed directly for each individual, using longitudinal data with repeated
observations on both instruments, X and Y, for each individual in the MI survey sample. If health state X
unambiguously improved (say) from period t to period t + 1, then we would expect instrument Y to show
an improvement also. We have been able to find no longitudinal survey containing both the EQ-5D-3L
and EQ-5D-5L in multiple waves; however, it is still possible to assess monotonicity indirectly in a
cross-section by making comparisons across appropriately selected sample groups.
Choose a specific reference health state, x. Define a subset of the population, S(x), as the set of people
who, if interviewed, give a response X = x, and another set, W(x), of people who would report a state
worse than x. The population measure, MW(x), of monotonicity relative to the group with worse
reported health states is then the probability that a person j selected randomly from set W(x) would
report worse health than a person i selected randomly from S(x), using instrument Y, just as the person
does using instrument X. Defining the symbol ≺ to mean ‘unambiguously worse in health terms’, the
measure MW(x) is written formally as:
MW(x) = Pr(Y j ≺ Y ijXi = x, X j ≺ x). (17)
Note that there is a natural lower bound forMW(x). In the extreme case where X and Y are independently
distributed (which should not be the case if they are conceptually related measures), the event Yj ≺ yi
would be independent of Xi and Xj and would occur with a probability of 0.5. Thus, an estimate ofMW(x)
close to 0.5 would suggest very serious inconsistencies between the two measurement instruments for
health states of x and worse.
There are many possible variations on this measure. We can also use a comparison group with better
health states than x, rather than worse, leading to a parallel measure:
MB(x) = Pr(Y j ≻ Y ijX i = x, X j ≻ x), (18)
where the symbol ≻ means ‘unambiguously better in health terms’. MW(x) and MB(x) need not give the
same result; for example, if people find it more difficult to give consistent responses when they are
describing a currently poor health state, we can expect MW(x) (summarising a comparison between
person i in poor health and person j in even poorer health) to give a lower monotonicity rate than
MB(x), which compares person i with a person j in better health.
The measures MW(x) and MB(x) are based on only partial orderings of health states, as many pairs of
health states cannot be ordered unambiguously (for example, EQ-5D-3L state 22321 is unambiguously
better than 33332, but cannot be ordered relative to 23312 without a utility tariff to trade off the
pain dimension against the self-care and anxiety/depression dimensions). However, we can also apply
the monotonicity analysis to utility values rather than health descriptions, which widens the range of
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comparisons to cover a full ordering. If the utility scoring systems for instruments X and Y are u(X) and
v(Y), then the utility-based version of measure MW(x) is:
MW(x) = Pr(v(Y j) < v(Y i)ju(X i) = u, u(X j) < u), (19)
where u is a chosen reference utility value. Here, the monotonicity measure is a joint measure of two
things: coherence of the underlying survey responses X and Y and of the structures of the utility tariffs
u(.) and v(.).
To illustrate this method, we use the FORWARD data set described in Chapter 4, Case study data set:
FORWARD, on RA. We summarise the main points here using simple plots of measures M^W(x) and M^B(x)
against the EQ-5D-3L utility values u(x), using all reference states x, which are given as responses by
at least 25 respondents. As an indication of statistical reliability, we also plot 95% confidence bands,
computed using the bootstrap with 200 replications. The results based on direct comparisons of health
states X and Y are shown in Figure 9. There are two main conclusions.
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FIGURE 9 Monotonicity measures for health descriptions: FORWARD data. (a) M^W (x); and (b) M^B(x).
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First, in large regions of the health spectrum, monotonicity rates are well below 100% and sometimes
close to the 50% rate we would find if X and Y were completely independent.
Second, low monotonicity rates are particularly evident for the measure MW(x) evaluated at low-value
health states x with utility value u(x) below about 0.4. Comparisons of poor health states with even
poorer states appear to be particularly problematic.
Figure 10 shows estimated monotonicity rates based on utility values rather than health descriptions.
Theoretically consistent utility value sets must give exactly the same pairwise ordering in every case
where the health descriptions can be unambiguously ordered, because Yj ≻ yi is equivalent to υ(Yj) ≺ υ(yi),
etc. However, the ≻ relation gives only a partial ordering, whereas utility values allow us to order every
state and thus bring more data points into the estimate at each point.
We use the UK value set for the three-level version of the EQ-5D5 and the English value set for the
five-level version6 (broadly similar results are found if we work instead with the ‘misery’ index that
sums the EQ-5D values across the five dimensions). In most cases, the use of utilities increases
monotonicity rates by about 10 percentage points. This increase is likely to be a consequence of the
0
10
20
30
40
50
%
 m
o
n
o
to
n
ic
 (
9
0
%
 C
I)
60
70
90
100
80
–0.4 –0.3 –0.2 –0.1 0.0 0.1 0.2 0.3
(a)
0.4 0.5 0.6
EQ-5D-3L utility score
0.7 0.8 0.9 1.0
0
10
20
30
40
50
%
 m
o
n
o
to
n
ic
 (
9
0
%
 C
I)
60
70
90
100
80
–0.4 –0.3 –0.2 –0.1 0.0 0.1 0.2 0.3
(b)
0.4 0.5 0.6
EQ-5D-3L utility score
0.7 0.8 0.9 1.0
FIGURE 10 Monotonicity measures for utility values: FORWARD data. (a) M^W (x); and (b) M^B(x).
ADDITIONAL METHODOLOGICAL ISSUES AROUND MAPPING
NIHR Journals Library www.journalslibrary.nihr.ac.uk
48
similar way that the two sets of utility values are constructed: both scoring systems build in theoretical
valuation axioms and both result from versions of the TTO valuation method.
Overall, the preliminary analysis gives some grounds for concern about the validity of MI reference
data sets and the mapping models based on them. There are several alternative interpretations of the
low monotonicity rates we have found. It would not be plausible to claim that the inconsistencies we
have found between EQ-5D-3L and EQ-5D-5L assessments reflect genuine changes in health-related
quality of life over the few minutes separating the EQ-5D-3L and EQ-5D-5L measures in an interview.
Another, perhaps more credible, possibility is that MI surveys, in which respondents receive two sets of
similar questions in sequence, are inherently unreliable in the sense that answers to the later version
of the EQ-5D instrument are systematically distorted by encountering the other version earlier. There
are several reasons, well documented in the survey methods literature, why this might happen:
satisficing behaviour by respondents to minimise effort rather than maximising accuracy; failure to
appreciate fully that the response scale has changed between the two versions; interview context,
because the two versions of the EQ-5D are immediately preceded by other, different, questions, the
nature of which might influence response behaviour; or simple annoyance at being asked similar
questions twice, resulting in a withdrawal of co-operation.
A second possible source of inconsistency is random measurement error affecting both versions of
the instrument. In this case there is no specific unreliability in MI data sets but failures arise through
random measurement noise, affecting responses to either version, whether asked alone or in tandem
with the other version. The consequences of this type of statistical ‘noise’ may be quite different from
the consequences of any behavioural distortions caused by question repetition.
A third possibility is that the two versions of the EQ-5D are interpreted by respondents as asking
about different concepts of health-related quality of life. For example, in the mobility domain ‘I am
confined to bed’ (EQ-5D-3L) may suggest a qualitatively distinct concept of physical disability and
dependency than ‘I am unable to walk about’ (EQ-5D-5L).
Further research is needed to understand the problem better, including research that assesses the
extent to which these issues arise for other instruments (both PBMs and non-PBMs) that ask questions
that are much less similar than the EQ-5D-3L and EQ-5D-5L. There is also a need to investigate the
existence and nature of measurement error. Wider use of test–retest trials in a controlled experimental
framework would be informative and could act as a basis for the development of evaluation methods
that are more robust to measurement error. The next section, Measurement error, discusses the complex
issues raised by measurement error in relation to CEA.
Measurement error
There are potentially two different sources of measurement error in the construction of QALYs for use
in an economic evaluation. First, individuals may make mistakes when filling in the responses to the
health instrument. It is possible that, at least in part, the high frequency of inconsistencies shown
in The validity of multi-instrument data sets used for mapping: the monotonicity concept is due to this
unobservable noise. Response error can in principle affect any observation, including those that appear
credible, so it is (arguably) preferable to allow for general response error rather than modifying or
discarding observations according to some arbitrary consistency rule as in van Hout et al.100
Second, there may also be error in the utility values. Assuming that true utility values vary randomly
across individuals, and that the valuation research (valuation data and subsequent modelling)
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successfully estimates the mean utilities conditional on any given health state X, then the actual
utilities are:
~υ = υ(X) + ε, (20)
where E(ε) = 0, independently of all other variables. Given the linear dependence of QALY on the utility
values, the inability of analysts to estimate the random utility component ε causes no bias. Therefore,
in this sense measurement error in the utility value can be ignored; we do this from this point on. Note
that misspecification and estimation error in the utility model underlying the form of υ(.) results in
systematic functional misspecification rather than measurement error, and we do not address that
issue here.
Again, we have two (vector-valued) health state measures, X and Y, provided by different questionnaire
instruments, and a set of discrete covariates Z describing the individual and their circumstances. There
is a utility value set, u(X) for the instrument X. Consider three hypothetical observational arrangements.
The first is a MI reference survey relating to a particular target population described by a distribution
f(X,Y,Z). We use the symbol f(.) to refer to any joint conditional or marginal distribution relating to the
MI reference population, with the arguments of f indicating the context. The MI reference sample is
used to construct a response mapping model that allows us to move between the alternative health
description systems X and Y.
The other hypothetical data sources are two clinical trials that are both representative of a target
population described by a distribution g(X,Y,Z). The target population is the set of individuals who are
believed to be potential beneficiaries of the intervention under trial. A type-1 trial observes only X and
Z and, thus, reveals the distribution g(X,Z), whereas a type-2 trial observes only Y and Z and reveals
g(Y,Z). The reference population and trial population are not necessarily the same, so f(X,Y,Z) and
g(X,Y,Z) are not identical.
Consider a generic and highly simplified CEA focused on the increase in expected QALYs, E6, achieved
by some intervention. The body making cost-effectiveness decisions will accept only QALYs based on
the utility tariff, υ(.), which has been constructed for the descriptive measure X. However, the decision-
making body will also accept values derived from a Y→X mapping applied to data from a type-2 trial
that uses the ‘wrong’ health outcome measure. The CEA objective is to determine whether or not the
ICER lies within a critical funding threshold or, equivalently, whether or not the expected utility E(u)
exceeds a specified policy threshold.
We consider the following five situations:
Case 1 – the baseline case where there is no measurement error and the required outcome measure
X is directly observed. In this case, there is no bias in the result of the CEA.
Case 2 – again there is no measurement error, but the trial observes the ‘wrong’ outcome measure,
Y rather than X. Consequently, mapping must be used, via a model estimated from data on X,Y,Z
observed in the MI reference sample. In this case there may be bias because the distribution of X|Y,
Z in the reference population may not coincide with the distribution of X|Y,Z in the trial population.
Case 3 – in this case X is observed directly in the trial so that mapping is unnecessary, but there is
random measurement error in the response X, giving the possibility of bias in the estimate of
expected utility and thus of the QALY gain.
Case 4 – this is a combination of mapping and measurement error: the trial observes Y as its
outcome measure rather than X, and there is measurement error in the trial data on Y and in the MI
data on X,Y. The measurement error thus affects QALY measurement directly but also indirectly by
measurement error bias in the parameters of the econometric mapping model fitted to the reference
data set.
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Case 5 – this is identical to case 4 except that we assume that the investigator has (somehow)
succeeded in adjusting the estimated mapping model to remove the measurement error bias in its
parameters. However, some bias may remain in the CEA results, from the measurement error in the
trial data on Y and mismatch between the reference and trial populations.
To illustrate the way that these biases may work in a practical application, we examine a hypothetical
trial based loosely on the structure of an actual evaluation: the CARDERA trial of combination drug
therapies for RA.70,96,101 The original evaluation was carried out using the EQ-5D-3L UK value set.5 Our
analysis assumes that the CEA will be based on the newer EQ-5D-5L instrument using the English
value set.6 There exist no data sets that will allow us to identify and estimate the full statistical
structure set, so we use a simulation approach. In simulation studies, it is important to specify the
assumed population processes to be as consistent as possible with what we can observe in actual data.
This involves calibration: ‘calculation of model parameter values consistent with data, rather than
econometric estimation’.102 In this application, our model parameters are the probability distributions
g(X,Y,Z), f(X,Y|Z) and measurement error probabilities. We construct these through a mixture of partial
econometric modelling and direct assumption. Here, we sketch the main details and give some
preliminary illustrative results.
We use the following assumptions to construct the calibrated model:
l We use the CARDERA empirical distribution as the assumed target population distribution of a
2-armed trial.
l We assume that reporting behaviour for the EQ-5D-3L and EQ-5D-5L is uniform across trial arms. This is
a critical assumption that, in one form or another, underlies any attempt at evaluation – if we cannot
assume that reporting behaviour is invariant to treatment, no reliable comparison between trial arms is
possible.We use the empirical distribution of FORWARD (see Chapter 4, Case study data set: FORWARD),
which covers patients with RA and matches well the target population of the CARDERA trial to construct
the distribution of the EQ-5D-5L conditional on the EQ-5D-3L and covariates. To calculate the true mean
QALY in each trial arm, we use a version of the multidirectional mapping model in Chapter 3, Indirect
methods: systems of ordinal regressions using copulas, which uses only age and gender as covariates
estimated on FORWARD.70
l We use the mapping model estimated by van Hout et al.100 to construct the mapping distribution.
l The mean discounted incremental cost, E(Δc) = £1500, is based loosely on average costs reported
for the CARDERA trial; we assume that expected cost is £6000 in trial arm 1 and £7500 in trial
arm 2.
l We assume a hypothetical measurement error process analogous to the ‘classical’ measurement error
assumption.Within each of the five dimensions of the EQ-5D, reporting error distorts measurement
symmetrically (except at the limit levels where symmetry is not possible) and independently, by no
more than a single position in the hierarchy of health states, and it is independent of the covariates
describing the individual and circumstances (see Hernández Alava and Pudney103 for other
hypothetical measurement error processes).
Illustrative results of this calibrated model of statistical bias are presented in Table 8. The first row
(case 1) gives the true mean QALY difference (0.080) and ICER (£18,780) for the target population
chosen via our calibration procedure.
The second row of Table 8 gives results for case 2 in which the EQ-5D-3L is observed and mapped
into the EQ-5D-5L, with no measurement error of any kind. The mismatch between the distribution
in the reference population used to construct the mapping function and in the trial target population
(based on the FORWARD disease-specific register) generates an upwards bias of 20% in the mean
QALY difference, which in turn reduces the measured ICER by 17%. The bias induced by mismatch of
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the reference sample used for mapping and the trial sample makes the intervention of trial arm 2
appear substantially more cost-effective than it really is. Note that the bias in the difference in QALYs
(and therefore also in the ICER) is large, despite the modest bias (–2%) in the QALY levels.
The third row of Table 8 deals with case 3, where the ‘correct’ measure, EQ-5D-5L, is observed, but
the health description is subject to small symmetric random reporting errors. The bias in this case is
reassuringly small: both QALY levels are understated by about 1%, but their difference, and the implied
ICER, are almost unaffected by the reporting error. The small negative bias in QALY estimation is a
consequence of ceiling effects for people reporting good health-related quality of life; for example, if
the true health state is 11111, then random measurement error can only result in a worse reported
state, never a better one.
The last two rows of Table 8 give results for cases 4 and 5 in which the EQ-5D-3L is observed with
measurement error and mapped into the EQ-5D-5L (which is also observed with error in the reference
sample). The fourth row of Table 8 shows the effect of ignoring the measurement error and the last
row gives the results for the case where mapping is assumed to have been corrected for measurement
error. Even small degrees of measurement error, as assumed here, lead to large changes in the QALY
calculation (–45% in trial arm 1) and even larger changes in the QALY differences between the two
trial arms (56%), leading to a reduction in the ICER of 36%. Adjusting the mapping for measurement
error reduces the bias in the QALY calculation but still leaves a large downwards bias in the ICER of
17%. This is due to the combined effect of the mismatch between the trial target population and the
mapping population and the reporting error in the trial itself.
We found that the distributional mismatch between the trial target population and the mapping population
is the main potential source of bias for any CEA involving mapping.We are not aware of any research in
this area but our preliminary results show that it can have serious consequences. Measurement error in
health responses is a source of bias regardless of whether mapping is used or not. In our simple example,
mapping increases the size of the bias but, in principle, mapping may make things better or worse, since
there might be offsetting biases. If it were possible to correct for measurement error in estimating the
mapping model, the biases would change. In our illustrative example, adjusting for the measurement error
in the mapping model reduces the bias but, in general, adjusting for measurement error in mapping may
reduce or increase the bias and may make the results more or less comparable with results from trials
requiring no mapping. Measurement error in the health description is not only a problem that affects
mapping models; it also distorts straightforward evaluations that require no mapping operations. This
raises the question of consistency across mapped and direct studies, and even the possibility that
‘correcting’ the mapping model for measurement error, as proposed by Lu et al.,103 may make even the
TABLE 8 Bias calculated for calibrated cost-effectiveness model
CEA setting
Arm 1
QALY
Bias in
QALY (%)
QALY
difference
Bias in QALY
difference (%) ICER (£)
Bias in
ICER (%)
Directly observed EQ-5D-5L,
no measurement error
2.6724 – 0.0798 – 18,781 –
EQ-5D-3L→EQ-5D-5L mapping,
no measurement error
2.6064 –2 0.0964 20 15,552 –17
Directly observed EQ-5D-5L,
measurement error
2.6444 –1 0.0803 0 18,688 –0
EQ-5D-3L→EQ-5D-5L mapping,
measurement error
1.4660 –45 0.1248 56 12,015 –36
EQ-5D-3L→EQ-5D-5L bias-adjusted
mapping, measurement error
2.5769 –4 0.0963 21 15,582 –17
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mapped and direct evaluations less, rather than more, comparable. Moreover, there is no generally
accepted set of assumptions about the nature of measurement error, nor any corresponding robust
method of correcting mapping models for measurement error bias.
We have presented here some illustrative examples of the type and size of the effects we are likely to
see, based on a calibrated model. More research is needed into every aspect of this issue, which is of
critical importance for practical policy analysis.
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Chapter 6 Discussion and conclusions
This report sets out new findings in the field of mapping. Developments in several areas aredocumented and tested in case studies.
One of the key shortcomings in the application of mapping models in existing literature has been the poor
performance of commonly applied statistical models. Despite the fact that such models systematically
mispredict, in some circumstances potentially giving a false picture of the real health benefits of treatments
(see Chapter 2, Direct methods), and that there now exists a large amount of supporting empirical evidence,
the application of these methods continues. This has led to widespread mistrust of mapping in general.
For mapping to be a reliable approach for bridging the gap between the utility-based estimates required
for cost-effectiveness analyses and the type of evidence often generated by clinical studies, it requires
statistical methods that yield unbiased results. There is nothing inherently different between this and
other regression-based inputs to cost-effectiveness models, though some authors claim otherwise.104
The requirement for new methods owes much to the challenging nature of the distribution of health
utility data. These challenges are present across disease areas and the different generic PBMs used to
generate health state utilities. They require flexibility in the statistical modelling methods and a degree
of adaptation of methods to suit the peculiarities of the various PBMs.
We demonstrated the inherent limitations associated with the application of linear regression in Chapter 3,
Development of methods for mapping. We used data from a large sample, a case study of patients with RA, to
estimate models and develop graphical methods for illustrating model performance across the spectrum of
disease severity. Plots of the predicted means versus data group means and of the distribution of the data
versus the distribution derived from the estimated model are very useful to aid understanding of differences
between models, and the potential impact of those differences when translated into economic evaluation.
When estimating a mapping model, the analyst should consider if the model might be misspecified.We
would encourage any analyst to consider if the assumptions are reasonable and these graphical displays
can help with this issue.
Some progress towards developing suitable mapping models is evident in existing literature. In particular,
the use of bespoke distributions used in a mixture modelling framework has previously been shown to
perform well when mapping to the EQ-5D-3L.51 The primary aim of the research reported here is to
develop this and other methods further, and to test their performance in a series of case studies that
use a variety of disease areas and target PBMs.
In particular, we have focused on three classes of methods in addressing this aim: the ALDVMM bespoke
mixture model, beta-regression-based methods and developments of multidimensional response mapping.
Chapter 3, Development of methods for mapping, describes these developments, their rationale and a
variety of options to consider in the application of each broad class of model.
We then used seven case studies to apply and further study these methods. These case studies
provided 15 different data sets in which mapping models were estimated using different approaches.
The data included the four most commonly applied generic preference-based instruments (EQ-5D-3L,
n = 11; EQ-5D-5L, n = 2; SF-6D, n = 1; and HUI3, n = 1) and covered a broad range of diseases
including cancers, asthma, heart disease and head injury. The data were collected from randomised
clinical trials, disease registries, bespoke patient survey studies and the UK NHS PROMs programme.
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The following main findings have implications for mapping practice and potential future research:
l The evidence shows that linear regression is not an appropriate method for mapping. This is
illustrated in Chapter 3, Predictions: mean versus distribution, with a sample of data from the
FORWARD database, in which we demonstrate how model performance can be assessed. This is
further illustrated in three case study applications in Chapter 4, Unidirectional case study comparisons.
Linear regression always performs poorly and is universally worse than models estimated using the
other direct methods we examined. This finding is in line with previous studies.
l Findings from this research show that mixture-based models are capable of providing very accurate
results irrespective of the target PBM. However, they need to be applied with considerable
attention given to the specific situation. These are more sophisticated models than many analysts
will be familiar with; they require a greater degree of statistical experience and judgement on the
part of the analyst than for simpler models to ensure that they are estimated appropriately and
provide reliable results.
l We developed freely available software commands to enable the application of mixture-based
methods. These commands, available for Stata, cover ALDVMMs (aldvmm)67 and mixture models
using the beta distribution (betamix).64
l Several features of the EQ-5D-3L informed the development of the mixture-based models. These
are less prominent in other PBMs, particularly the size of the gap between full health and the next
feasible health state, and the multiple modes lower down the distribution. Yet, for all applications,
we found that the inclusion of these features remains important for model performance, whether
using the ALDVMM or beta mixture models.
l Optimal mixture models tend to require between three and four components. This may have
implications for the size of data sets required for mapping studies. The smallest case study used
in this investigation provided 852 observations (for the AQLQ-S asthma study) in which four
component ALDVMM and beta-based mixture models were estimated.
l We also find that there is a requirement for measures of disease severity to be incorporated into
predictions of the component probabilities as well as within the components themselves. In many
cases, the optimal specification also included age in the component probabilities.
l Optimal beta-based mixtures and ALDVMMs perform extremely well in the case studies owing to
their flexibility. It is not possible to draw universally applicable guidance between these two broad
types of models. Beta-based mixtures tend to require at least some probability masses but these are
the result of practical considerations rather than theoretical, require additional parameters to be
estimated and represent an increase in the number of models that need to be considered. In our
applications we found that the relative simplicity of ALDVMMs gave a better fit to the data
in general.
l Response mapping could not always be performed because it relies on sufficient observations for
each level within the PBM descriptive system. For PBMs that are based on more complex descriptive
systems, for example with increases in the number of response levels, so the likelihood of observing
data in all levels diminishes. The case study in people with asthma demonstrates this for both the
EQ-5D-5L and HUI3.
l In those unidirectional case studies in which response mapping methods were applied, we found
that the direct methods were better performing.
It is important to note that these case studies address the issue most commonly encountered in
mapping, where the requirement is to predict a generic, preference-based outcome utility value from
some non-preference-based outcome. Less common, but of substantial importance in allowing decision-
makers to assess health technologies using the same outcome measure, is the issue of mapping from
one PBM to another. Unlike the traditional mapping case, here our interest is in the ability of the
statistical model to allow predictions to be made in either direction. We developed methods and
demonstrated their performance (see Chapter 3, Indirect methods: systems of ordinal regressions using
copulas, and Chapter 4, Multidirectional mapping case study), using a case study to map between the
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EQ-5D-3L and EQ-5D-5L. These methods embody several important features for this type of mapping
and provide a powerful modelling technique:
l The approach is designed for mapping between the EQ-5D-3L and EQ-5D-5L, in either direction,
in a mutually consistent way.
l It does not make any assumptions about the two instruments but instead allows the data to
determine what is necessary. In particular, it avoids the assumption that the EQ-5D-5L response
scale is simply a more detailed categorisation of the same concept in the EQ-5D-3L scale.
l Covariates are included with no assumption that they influence EQ-5D-3L and EQ-5D-5L responses
in the same way.
l Copulas are used to specify the bivariate distribution of each EQ-5D-3L–EQ-5D-5L pair of responses.
This is a way of capturing the associations between EQ-5D-3L and EQ-5D-5L responses, but again in
a flexible manner that does not require the assumption that the strength of the association is the
same in all parts of the health distribution.
l A random latent factor allows dependence across the five domains of the EQ-5D, reflecting
common underlying causes and individual-specific response styles.
The Stata command bicop72 was developed to allow analysts to estimate a simplified version of the
model of the five bivariate ordinal regressions for each dimension separately. The command eq5dmap
allows mapping between the EQ-5D-3L and EQ-5D-5L based on estimated bidirectional mapping
models.71
The development of this approach also provides several potential features that may improve response
mapping, which generally did not perform well in the unidirectional case studies reported here.
Response mapping approaches do offer the potential advantage of being closely aligned to the data-
generating process for utility values from PBMs, and they have practical advantages in allowing
different tariffs for different countries to be applied.
Summary of research recommendations
In the process of developing flexible models for mapping, we have uncovered some important issues.
The research presented here provides a basis for developing and understanding these issues further.
We summarise our research recommendations in what we see as their order of priority in this section.
Typically, it is recommended that some qualitative-type assessment is undertaken of the degree of
conceptual overlap between instruments before undertaking a mapping study.32 We have gone further
and examined the extent of conflicts between the orderings of health states in a case study of the
EQ-5D-3L and EQ-5D-5L using the concept of monotonicity. Further research is needed to gain a
better understanding of the problem. Furthermore, future research should examine the use of
monotonicity measures for informing mapping studies that rely on other measures less similar than
those in our case study.
We found that distributional mismatch between the trial target population and the population used
for mapping is a potential source of bias for CEAs that use mapping. More research is required to
understand the likely size of the biases due to distributional mismatch.
We have shown that there are many sources of measurement error in the outcomes used in mapping
studies. Some of these are present, and to differing degrees, in the responses being analysed as part of
the mapping process. Some are also present when those same measures are used in clinical studies to
assess the effectiveness of health technologies, or in clinical practice when assessing patient response.
Given this, future research is needed to generate evidence of how and when to adjust for
measurement error in mapping.
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It is sometimes not feasible to undertake response mapping because of the small numbers of
observations in some response categories. This is an issue that may become more prevalent as PBMs
introduce more response levels to their descriptive systems. Furthermore, methods often did not
perform well compared with direct methods in this study. Nevertheless, response mapping methods
maintain a degree of appeal because they are closely related to the data-generating process of PBMs
and offer an easier means of generating results that can be used internationally. The development of
response mapping methods that harness a greater degree of flexibility remains an area for future
research.
Although we have demonstrated the clear benefits of flexible mapping methods, it is sometimes the
case that mapping studies are undertaken in very small data sets. This may be because no larger
studies have been conducted and, in some disease areas, may not be feasible, for example where
patient numbers are very small. It is not clear what should be done in this setting. Future research
should investigate options that may include some type of bias adjustment process to be applied to
simple methods and single component models (such as the underlying distribution of the ALDVMM).
It may be the case that mapping with very limited data is simply best avoided.
Those who design clinical research studies should be aware of the need to collect data that service the
needs of economic evaluation. The inclusion of relevant PBMs in all types of clinical studies should be
more widespread. In many situations, the inclusion of a PBM in the key clinical trials would obviate the
need for mapping. However, the value of data from PBMs applied in large-scale disease registries and
other observational studies is obvious from the work reported here. The value generated from the
work of large-scale studies such as FORWARD, the National Databank for Rheumatic Diseases, should
serve as an exemplar to other disease areas. The collection of these data does not need to be designed
with a specific current research question in mind. The decision to include both the EQ-5D-3L and
EQ-5D-5L simultaneously in one wave of FORWARD has yielded huge value far beyond decisions
relating to the assessment of health technologies for patients with rheumatic disease.
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